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SUMMARY

1.

Well established models of hemorrhage and sepsis in the rat have been
used to study possible roles of prostaglandins (PGs) during these con¬
ditions.

2.

Direct measurement of plasma PGE and PGF0

2a

levels before and during hemor-

rhage, by radioimmunoassay, yields large variations and reveals no pat¬
terns of change.

3.

The single pass pulmonary metabolism of injected PGE£ was dramatically
decreased following 75 minutes of hemorrhagic hypotension.

Associated

with the decrease in pulmonary PG metabolism was an increased retention
of radioactivity by the lung tissue.

This is the first in_ vvv£ demonstra¬

tion of altered metabolism of PGs during hemorrhage.

4.

Treatment with indomethacin, a well known inhibitor of PG synthesis,
caused a significant decrease in survival following 75 minutes of hemor¬
rhagic hypotension at 40 mm Hg.

These effects were not reversed by in¬

fusion of PGE^ (0.1 yg/kg/min) alone.

5.

In a model of sepsis produced by cecal ligation and puncture, indomethacin
treatment during early sepsis was found to be deleterious.

During late

sepsis, however, indomethacin treatment did not further diminish the low
survival rate of animals.

The present results demonstrate, for the first

time, adverse effects of indomethacin on survival following sepsis.
suggests that PGs play a protective role during sepsis.

vi i

This

Summary continued

6.

It is concluded that PGs have a protective role in hemorrhagic hypo¬
tension and early sepsis.

The mechanism of protection is not known,

but probably involves sparing of tissue ischemia by vasodilation.

vi i i

GENERAL INTRODUCTION

Hemorrhage and sepsis are pathophysiologic situations characterized by
significant alterations in circulatory dynamics, tissue perfusion, cellular
energetics and function.

These alterations lead eventually to cell death,

organ failure, and, all too frequently, demise of the organism.

Despite

the vast literature dealing with clinical and experimental observations of
shock, many questions remain unanswered (20, 42, 281).
In particular, there are several major unanswered questions regarding
the control of the vascular bed at several levels:

the relationship of the

pump function of the heart to the resistance and capacitance vessels; the
relationship of organ function to organ perfusion during altered circulatory
states; the interactions of the microvasculature with cell energetics and
perfusion.
Prostaglandins (PGs) have been demonstrated to produce striking effects
on many tissues even at low concentrations.

Two of the circumstances in

which PGs have been implicated are hemorrhage and sepsis (184).

Yet little

is known concerning the effects and role of PGs during such adverse circu¬
latory conditions.

Therefore, the studies described in this thesis were

undertaken in an attempt to determine possible roles of prostaglandins in
hemorrhage and sepsis.

.

2.
BACKGROUND

1.

Hemorrhage
Hemorrhagic hypovolemia produces circulatory compromise in a number of

different ways, as many reviewers have pointed out (20, 147, 281).

The fun¬

damental problem during hemorrhage is decreased circulatory volume
(239), which leads in turn to hypoperfusion, tissue hypoxia, and cell in¬
jury.

The organism responds to this circulatory insult with a complex neuro-

humoral response (6, 58, 71, 179, 223), which is designed to direct the resi¬
dual volume preferentially to vital organs (i.e., brain, heart, liver, and
kidneys), even at the expense of other sites.

This response is not entire¬

ly salutary in prolonged hypovolemia, however, since continued hemorrhagic
hypotension is associated with several pathologic processes.

The nature of

these adverse processes has been recently reviewed by Zweifach and Fronek
(281).
Cardiac function, for example, has been found to deteriorate during
prolonged hypovolemia (103, 153), despite the fact that coronary blood flow
is preferentially maintained at adequate rates.
the deterioration of cardiac function include:

Proposed explanations of
a failure of sympathetic

output in late hemorrhagic shock; alterations in cell metabolism leading to
decreased pump function; and the effect of toxic factors, such as "myo¬
cardial depressant factor" (92, 149).

Another possibility is that the con¬

trol mechanisms in the coronary bed function less effectively during hypo¬
volemia; this might be due to alterations in any of a number of local and
humoral factors, including the PGs.

.
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The circulatory failure resulting from hemorrhagic hypotension may pro¬
duce significant alterations in renal blood flow and function.
lar the following effects are seen:

In particu¬

the redistribution of blood flow in

favor of the inner cortex and medulla (198), activation of the renin-angio¬
tensin system (178), and alterations in renal concentrating ability, which
involve anti-diuretic hormone (ADH, ref. 234).

The genesis of these changes

is described as a complex interaction of neuro-humoral vasopressor effects
and local vasodilation (17).
Alterations in pulmonary blood flow and function during hemorrhage have
been reviewed by Bryant et_ al_. (33 ) and, more recently, by Sykes (249).

In

brief, the pattern of intrapulmonary blood flow is changed so that the lower,
dependent areas receive more flow (255).

These gravity favored areas have

been identified as the site of subsequent changes in capillary permeability
(49, 131, 233, 254) and of malfunction of surfactant-producing Type II pneumocytes (176).

These changes may also contribute to decreased compliance (50)

and to the increase in pulmonary vascular resistance (83).

In addition, al¬

terations in the pulmonary vascular bed and capillary endothelial membranes
may lead to changes in other non-respiratory functions of the lungs, such as
metabolism of circulating hormones (89).
Immunologic (8) and hematologic (158) changes have also been documented
during hemorrhagic hypotension.

It must be borne in mind, however, that ex¬

perimental techniques, including heparinization, may contribute to these
changes.

Alterations in hepatic function have also been well documented

during hemorrhage, and recent work has correlated functional changes with
alterations in cell ultrastructure and function (87).

4.

A recurrent theme in the above mentioned alterations in organ function
is the associated changes in regional blood flow.

These effects appear to

be mediated by catecholamines and humoral vasoactive substances, but modu¬
lated subsequently at the level of the microvasculature (281).
The microvasculature is itself subject to diverse factors during hemor¬
rhage, including acidosis (140, 274), catecholamines (6), and the kallikrein
kinin system(25, 220).

There may be other factors which affect the micro¬

vasculature, such as prostaglandins (167) and unidentified local metabolites
The response of the microvascular bed has been observed during hemorrhage by
direct microscopy.

In skeletal muscle (107, 121) hemorrhage induces con¬

striction of small arteries and veins in the early stages, followed by ve¬
nous dilation at a later stage.

In the enteric bed (85) no changes in ar¬

terial or venous tone have been noted, but capillary flow has been observed
to decrease.

These changes are consistent both with the

decrease in blood

flow to most vascular beds and with the degree of variation from tissue to
tissue of vasoconstriction-vasodilation.
)

The consequences of diminished flow during hemorrhage have also been
documented at the cellular level.

The effects which have been observed in¬

clude the production of hypoxia (196, 240), alterations in cell membrane
function leading to changes intracel1ular fluid and electrolytes (64), and
significant alterations in cellular energetics (21, 38).

The defect in cell

energy production may be due to many factors, among which the following are
prominent:

altered microcirculation which may limit substrate availability

to cells; membrane alterations which include defects in membrane transport
(224) and response to hormones (40); and changes in the capacity of cells to
provide energy for or to control active transport.

Decreases in cellular

.
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cyclic nucleotide levels and high energy phosphate compounds have been docu¬
mented during hemorrhage (39).

Since many intracellular functions are ener¬

gy requiring, the documented decrease in available intracellular energy stores
may impair tissue function as well.

Indeed, this has been documented (21).

In summary, hemorrhagic hypotension might be conceived as the stimulus
for the organism to respond with measures which simultaneously vasoconstrict
and vasodilate.

The former is protective of critical organs and is due to

the action of sympathetics, renin-angiotensin, and perhaps other humoral
substances.

Vasoconstriction when prolonged is, however, injurious to cells.

The organism must also respond with actions to mitigate the injurious ef¬
fects of vasoconstriction.

It does so by vasodilation of local micro-

vascular and small vessel beds.

A key to understanding the pathophysiology

would appear to lie in the interaction of neuro-humoral and local factors at
the level of the local circulatory bed.

2.

Sepsis
For the sake of clarity, sepsis is defined here as the severely altered

pathophysiologic state resulting from infection, with or without associated
septicemia.

In spite of the frequent occurrance of sepsis, little is known

of the complex mechanism by which such serious infections alter physiologic
parameters and lead to high mortality (170, 271).

A number of investigators

have attempted to address the problem of the pathophysiology of sepsis and sev¬
eral approaches have been used.

Previous work falls into three broad classes:

clinical studies of septic patients; animal models using purified endotoxin;
and animal models of bacteremia, usually produced either by injection of live
organism, by abscess formation, or by peritonitis.

The relationship of the

experimental models to clinical observations is still unclear (271).

.
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The many clinical descriptions and studies (37, 55, 108, 146, 170, 177,
189, 267, 275, 276) have been concerned, in general, with empiric observation
of the clinical syndrome, although the more recent advent of clinical hemo¬
dynamic monitoring has afforded the possibility of documenting the dramatic
hemodynamic and metabolic alterations which occur during sepsis.

Briefly,

the clinical studies document an early "warm" phase, characterized by in¬
creased cardiac output, vasodilation, hyperventilation, and hyperglycemia.
This is followed by the "cold" phase, which is associated with diminished
cardiac output, vasoconstriction, hypovolemia, oliguria, acidosis, hypo¬
glycemia, and high mortality (42, 146, 267).

Sepsis, therefore, is a com¬

plex and evolving phenomenon, which is capable of producing profound physio¬
logic alterations.
Christy has written a thorough review of the pathophysiology of sepsis,
although it is vintage 1971
with sepsis.

(42).

These include:

He describes several features associated

1.) depression in cardiac, renal, and pul¬

monary function in the late stage of sepsis;

2.) marked increases in many

humoral factors, such as acetylcholine, bradykinin, catecholamines, hista¬
mine, and serotonin;

3.) decreases in other circulating factors such as

coagulation factors and complement;
logic-inflammatory reaction; and
circulation.

4.) coagulopathy;

5.) a major immuno¬

6.) significant changes in the micro-

The microcirculatory changes are characterized pathologically

(169) as a generalized Shwartzman reaction.

The underlying mechanisms for

the phenomenologically observed alterations, however, are not known.
The prominence of immunologic features in sepsis has prompted investiga¬
tion and mechanistic speculation concerning the role of endotoxin in sepsis.

.
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Endotoxin is a 1ipopolysaccharide present in the cell wall of most gram¬
negative organisms (60), which, when injected into animals, produces hemo¬
dynamic alterations similar to those described in late sepsis (260), as well
as high mortality.

Because of these observations, many investigators have

studied endotoxin shock as a model of sepsis, assuming that their observa¬
tions of endotoxin effects will contribute to the understanding of human
sepsis and help to formulate treatment programs for clinical use.
not necessarily true(271).

This is

Some features of sepsis, such as activation of

immunologic host defense systems, may be ascribed appropriately to endotoxin
(175), but other features, such as hemodynamic effects, cannot be so read¬
ily assumed to be due to endotoxin.

Furthermore, study of endotoxin shock

has been plagued by other problems, such as:

1.) variations in endotoxin

preparations which may lead to vastly different effects (175);

2.) confu¬

sion over amount of endotoxin to be administered, for it is likely that
large doses (LD^qq, with 2-20 mg/kg) correspond more nearly with anaphy¬
laxis than with bacteremia; and

3.) species variations which further com¬

plicate efforts to translate conclusions based on endotoxin studies to hu¬
man sepsis.

Finally, there is confusion over the actual role of endotoxin

in clinical sepsis, since quantification has detected concentrations of
endotoxin in the range of pi cograms per milliliter; this differs from exr

perimentally used quantities by a factor of 10

(209, 271 ).

Animal models of bacteremia, as recently reviewed by Wichterman and
associates (271), have been intended to reproduce more accurately human sep¬
sis.

The major difficulty with these models has been reliability and repro¬

ducibility of the bacteremic insult.

A recently described model of cecal

8.

ligation and puncture in the rat has been found to cause bacteremia in all
animals within six hours and to produce a high mortality rate (272).

In

addition, this model is notable for its imitation of the hemodynamic and
metabolic alterations of human sepsis, in particular for an early phase of
hyperdynamic circulation and hyperglycemia (272) and a later phase of de¬
pressed hemodynamics and hypoglycemia.
been documented in a canine model

(143).

Similar hemodynamic findings have
It is hoped that these models

will allow inquiry into the mechanism of septic injury, without the com¬
plicating concerns of applicabi 1 ity, as has been noted for endotoxin models.
In summary, the clinical features of sepsis have been observed and re¬
ported by many authors, but the roles and significance of the various fac¬
tors are still largely unknown.

Concern over the appropriateness of various

animal models has made the pathophysiology of sepsis difficult to understand
in a controlled manner.

3.

Prostaglandins
Prostaglandins (PGs) are a set of ubiquitous compounds which have been

the subject of extensive research during the past decade and the subject of
an equally extensive literature.

Because this literature is so immense, it

will not be possible to delineate all of the PG effects in this section.
The major effects of PGs are, however, listed below, and a more detailed
description is provided in the Appendix (p.73).
The PGs are unsaturated fatty acid derived compounds synthesized by
virtually every type of mammalian tissue yet studied.

The biosynthesis re¬

quires the release of arachadonic acid (AA) from cell membrane phospholipids,
which occurs following a number of physical, chemical, and physiological

'
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alterations.

AA is then transformed by a series of membrane bound enzymes,

as shown in Figure 1, into the PGs:

PGE, PGF, PGI, and thromboxane A (TXA).

These are the compounds of greatest physiologic significance.

The plasma

half-lives of these PGs are short, however, ranging from 30 seconds (TXA^)
to a few minutes (PGs E, F, and

l^).

The primary PGs (PGE and PGF) are in¬

activated in the pulmonary vascular bed, primarily by the action of the
intracellular enzyme 15-hydroxy-PG dehydrogenase.
down primarily by hydrolysis in plasma.

PGI and TXA are broken

The pulmonary metabolism of the

primary PGs assures, in general, that the effects of these two PGs (E and F)
are primarily local tissue effects.
The variety and magnitude of effects which PGs evoke are striking.
For the most part, the vascular effects of PGs may be summarized by the
statement that PGE0 and PGI0 are vasodilators and PGF0
c

constrictors.

c

ca

and TXA0 are vasoc

This has been noted in many vascular beds in a number of

species, although there are exceptions.

For example, the rat renal bed has

been found to vasoconstrict in response to PGE2.
The PGs have a number of renal effects as well.

They are thought to

constitute a major part of the renal vascular autoregulatory response.

In

addition, they are thought to contribute to the control of systemic blood
pressure, to the control of renin release, to adjustment of fluid and
electrolyte balance, and to mediation of erythropoietin synthesis stimulation.
In the lungs PGs have bronchial smooth muscle effects analogous to
those in vascular smooth muscle.

Thus, PGE^ is bronchodilatory and PGF^

is bronchoconstrictive (PG^ and TXA^ are largely unstudied, since they
are relative newcomers to the field).

The PGs are thought also to contri¬

bute to the pulmonary response to hypoxia and anaphylaxis.

.

.

FIGURE 1

10.

BIOCHEMISTRY OF THE PROSTAGLANDINS (PGs)

Membrane
Phospholipids
Arachadonic Acid (Eicosatetraenoic Acid)
T

13,14-dihydro,15~keto-PG

LEGEND:
Enzyme
1 :
23:
4:
5:
6:
7:
8:
9'.
10:
11:

Phospholipase A^
Cyclooxygenase
PG Endoperoxide E Isomerase
PG Endoperoxide Reductase
Prostacyclin Synthetase
Thromboxane Synthetase
9-keto Reductase
15-hydroxy-PG Dehydrogenase
PG A13 Reductase
non-enzymatic hydrolysis
non-enzymatic hydrolysis

1:
2:

Corticosteroids (?)
Nonsteroid anti-inflammatory
agents (aspirin, indomethacin,
etc.)

5:
6:

1 5-peroxy-arachadonic acid
Imidazole, benzydamine

8:

Indomethacin, ?furosemide

-•

The gastrointestinal effects of PGs include smooth muscle activity
(PGE^ modulates motility) and protective effects against ulceration.
endocrine effects are prominent in the reproductive system.

The

Recent investi¬

gations have implicated PGs and cAMP in the control of hormone release.
In the nervous system both central and autonomic effects have been de¬
scribed.

Mediation of fever and neurotransmission effects have been ascribed

to PGs in the central nervous system.
fects:

More important are the autonomic ef¬

PGE,-, inhibits adrenergic release prejunctionally and enhances choli¬

nergic release; PGE2 also, in general, modulates effects of sympathetic stimu¬
lation of vascular tissue by vasodilation.
Control of local circulation seems to be a major function of the PGs.
Not only do vasodilatory PGs oppose the vasopressor effects of adrenergic
stimulation, but they also appear to modulate or mediate the effects of a
number of circulating vasoactive factors as well, such as angiotensin and
bradykinin.

In general, the PGs seem to function as homeostatic regulators

of local circulatory beds in response to stimuli noxious to tissues.
Recent work indicates that PGI^ and TXA^ play major and opposing roles
in the control of platelet aggregation.

PGI2 inhibits aggregation, whereas

TXA2 is a potent stimulus for platelet aggregation.
The central mechanism of PG action, as has been learned principally
from the study of platelets, is modulation of intracel 1 ular cAMP.

The PGs

have also been implicated in the control of intracellular calcium movements
and stores.

The precise details, however, of the interactions of the PGs,

cAMP, and intracel1ul ar Ca

2+

are still unknown.

12.

It may be taken as a general hypothesis that the PGs subserve the func¬
tion of membrane messengers, i.e., the release of PGs from altered or in¬
jured membranes leads to stimulation of cells.

Whether the cell(s) which

is influenced is the same cell, nearby, or distant is still a matter of in¬
vestigation, although most investigation suggests that PGs are primarily
local hormones, affecting nearby cells.
Study of PGs and PG effects have benefited greatly from the use of in¬
hibitors of PG synthesis, particularly the nonsteroidal anti-inflammatory
drugs, such as aspirin and indomethacin (see Figure 1, step 2).

The di¬

rect measurement of PGs, on the other hand, has been problematic and the
significance of plasma PG levels has also recently been questioned.

More¬

over, the PGs are present in tissues in small concentration and are effect¬
ive in equally small concentrations (i.e., 10~^ to 10~^ M).
biochemical measurement techniques are not useful.
assays must be used.

Thus, ordinary

Instead, very sensitive

At present, radioimmunoassay and gas chromatography-

mass spectrometry are the best methods of measurement; the latter is cur¬
rently believed to be the more dependable.

;

13.

REVIEW OF RELEVANT LITERATURE

There are a number of clinical and experimental studies which indicate
that alterations in PG synthesis may be involved in the pathogenesis or
manifestations of a number of clinical situations.
PG synthesis and concentrations are:

Associated with increased

trauma, burns, shock, sepsis, malignant

tumors, fever, subarachnoid hemorrhage, pulmonary hypertension, and perhaps
others (184).

On the other hand, patent ductus arteriosus, peptic ulcer,

renal ischemia, and others have been associated with decreased PG synthesis
(184).

These, in conjunction with the striking effects observed at low PG

concentrations, suggest that they may play a role in the altered circulatory
dynamics of hemorrhage and sepsis.

Several previous investigators have ex¬

amined some aspects of this question.

1.

Hemorrhage and Prostaglandins
The circulatory insult of hemorrhagic hypotension is precisely the cir¬

cumstance in which one might expect to find increased PG synthesis.

This is

due to the fact that the microcirculation is affected during hemorrhage and
cells are subjected to hypoxia, which is a potent stimulus of PG synthesis
(161).

The decreased blood flow to organs and tissues, which leads to al¬

tered cell functions throughout the organism, might lead specifically to a
depression of cell membrane transport and metabolism of PGs by the endotheli¬
um in the lung.

This, in turn, might subject the organism to further in¬

creased PG levels.

In attempting to understand the role of PGs during

hemorrhage, a number of investigators have used several different approaches.
These have included:

1.) direct measurement of plasma PG levels during

.
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hemorrhage;

2.) assessment of metabolic capabilities of organs and cells to

inactivate PGs; and

3.) use of pharmacologic inhibition of PG synthesis or

of exogenous PGs to alter survival or physiologic parameters.
The possibility of direct measurement of plasma PG levels has attracted
several investigators.

Most have measured PGE levels, since PGE has signifi¬

cant vasodilatory actions, which might either ameliorate local blood flow or
exacerbate systemic hypotension.

PGE also has effects related to a number

of other vasoactive stimuli, i.e., sympathetic stimulation, angiotensin, and
bradykinin, so that alterations in PGE levels may affect the vasomotor activi¬
ty of these entities.

PGF2a has been studied rarely, perhaps because its

vascular activity is not believed to be as significant physiologically.
Studies concerning the newer PG compounds, PG I ^ and

have not yet been

reported.
The first report of elevated PGE during hemorrhage was that of Flynn
and associates (80).

They subjected the anesthetized dogs to hemorrhagic

hypotension to 60 mm Hg and obtained arterial blood for determination of
plasma PG levels by RIA.

They found an increase in plasma PGE from 0.34 to

1.3 ng/ml after 90 minutes of hypotension.

They also reported increased

levels, from 0.62 ng/ml baseline to 1.25 ng/ml after 60 minutes.

Jakschik

and co-workers (129) subjected anesthetized dogs to 45-50 mm Hg hemorrhagic
hypotension and used bioassay to determine arterial PGE levels.

These investi¬

gators found an increase from control levels which were immeasurably low to
levels of 2.6 ng/ml after 30 minutes; they associated the above time with
maximal compensation.

Johnston and Selkurt (132) subjected animals to hemor¬

rhage to achieve 60 mm Hg hypotension for 90 minutes, followed by further
bleeding to 35-40 mm Hg.

They observed an increase in PGE levels, as

ft!’
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measured by RIA, from 450 pg/ml to 740 pg/ml in arterial samples.

These in¬

vestigators (132) also measured renal output of PGE by renal vein sampling
and found that PGE output did not change during the period of hemorrhage.
When shed blood was reinfused, however, they noted a striking increase in
renal output of PGE from 8 ng/min baseline and during hemorrhage to 109 ng/min.
Most recently, Frolich (89) has reported increased PGE^ levels in aortic blood,
but not in right atrial blood, during an undescribed hemorrhagic insult in
both anesthetized and unanesthetized dogs.

Using gas chromatography-mass

spectrometry (GC-MS) he found a tremendous increase in PGE^ from basal values
of less than 50 pg/ml to values greater than 10000 pg/ml after 30 minutes
of hemorrhage.
132) that PGE

2

Thus, it appears on the basis of these studies (80, 84, 129,
levels increase during hemorrhage in dogs.

The possibility has been raised that part of the elevated arterial PGE^
levels might be the result of diminished pulmonary metabolism of circulating
PGE.

Hissen et a]_.

(117) presented data in 1969 that in retrospect suggests

decreased metabolism.

They found that PGE-| injected intravenously

during

hemorrhage produced increased arterial levels as assessed by increased inhibi¬
tion of platelet aggregation.

Jakschik and associates (128) lent support to

the hypothesis of decreased pulmonary metabolism.

Using bioassay, they found

an increase in the ratio of arterial to venous PGE.

Blasingham and Selkurt (30)

and Fletcher and Ramwell (74) reported similar findings using RIA.

They docu¬

mented a decrease in extraction ratio of PGs using mixed venous and arterial
blood.

(1 -(A/V)).

The findings of these three groups (30, 74, 128) are con¬

sistent with those of Frolich (84) using GC-MS.

These four investigations,

however, could not distinguish decreased metabolism from increased pulmonary
synthesis and release of PGE during hemorrhage.

Indeed, Frolich's data support

.
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the latter as the more important factor.

On the other hand, Flynn and Lefer

(81) found no decrease in the ability of rabbit liver, kidney, or lung homo¬
genates to metabolize PGE or P6F following systemic hypotension.

Whether or

not the altered metabolism seen in vivo by previous workers (30, 74, 117, 128)
was reversed by isolation and handling is not clear, however, so that caution
must be used in accepting the data of Flynn and Lefer (81) as evidence of in¬
tact metabolic capacity.

Nevertheless, the different in vivo and in vitro

findings do create confusion concerning the issue of alterations in pulmonary
metabolism of PGs during hemorrhage.
The experimental use of PG synthesis blockade both as therapeutic inter¬
vention and as pharmacologic tool has attracted many investigators.

Jakschik

and co-workers (129) noted an increase in mean arterial pressure (MAP) and
an increased blood loss following a moderate dose of indomethacin (1-2 mg/kg).
Johnston and Selkurt (132) reported that the same dosage of indomethacin did
not affect the small increase in arterial PGE they had observed, but did
block the large increase in renal release of PGE during reinfusion.

The

thorough study of Leffler and Passmore (150) showed that indomethacin in¬
creased systemic blood pressure by increasing systemic vascular resistance
in

dogs subjected to 3.5 hours of severe hypotension.

These authors hemor¬

rhaged animals to 30 mm Fig and gave indomethacin once the MAP began to fall
after reinfusion.

In particular, their investigation demonstrated increased

vascular resistance in the heart, brain, gut, and kidney, as well as a 57%
diminution in renal blood flow.

This study (150), therefore, suggests a pro¬

tective role for PGs in late hemorrhagic shock.

.
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A number of other reports have documented (by PG synthesis blockade)
the importance of PGs in the renal bed during hemorrhagic hypotension.
et. al_.

Bell

(23) showed that indomethacin inhibits the recovery of renal blood

flow following hemorrhage to 30 mm Hg.

Using microspheres, Data and co¬

workers (47) demonstrated decreased renal blood flow in animals treated with
8 mg/kg indomethacin prior to a 33% reduction in MAP.

They noted that the

decrease in blood flow was particularly evident in juxtamedul1 ary nephrons
and

in

the cortex.

Tyssebotn and Kirkeb0 (259) found similar results using

platinum electrode measurement of renal blood flow in dogs bled to 50 mm Hg.
They suggested that PGs play a role in dilating vessels throughout the kid¬
ney.

The studies of Henrich and associates (110, 111) have shown that PG

blockade with indomethacin or with R020-5720, a peripheral blocker of PG
action, leads to diminished blood flow and glomerular filtration rate.

They

also showed that the combined effects of denervation and angiotensin II block¬
ade returned blood flow to rates found in animals not treated with PG block¬
ade.

These studies strongly suggest that PG synthesis is increased in the

renal bed, perhaps to counteract the effects of the renal sympathetics and
of circulating angiotensin II, thereby maintaining renal blood flow.

Thus,

it appears that renal PGs exert a protective vasodilatory effect during
hemorrhagic hypotension.

This notion is consistent with studies on acute

renal failure induced by renal artery clamping (127) and by glycerol admini¬
stration (258, 270).
The work of Gerkes and Shand (87) on hepatic artery autoregulation is
analogous to the studies on the renal bed described above.

These investiga¬

tors found that indomethacin increased hepatic artery resistance during 33%
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hypotension as compared with untreated animals.

This observation suggests

that PGs play a role in vasodilation in the hepatic bed.
Studies have also been conducted to determine whether exogenous PG
would ameliorate the effects of hemorrhagic hypotension.

Glenn (91) re¬

ported that intravenous infusion of PGF^ led to prolonged survival time in
cats subjected to a lethal hemorrhage protocol.

Priano et al.

(211) reported

increased survival time and improved cardiopulmonary function in anesthetized
dogs bled to 40 mm Hg and given an intraventricular infusion of PGE-j at a
rate of 0.4 yg/kg/min.

Machiedo and associates (154, 155) reported prolonged

survival and improved cardiac and respiratory function in anesthetized dogs
bled to 30 mm Hg and maintained until they received 25% of shed blood, at
which time the remaining shed blood was returned and intravenous PGE-j was in¬
fused at a rate of 1 yg/kg/min.

Finally, in a more recent paper, Flynn and

Lefer (82) found that infusion of arachadonic acid intravenously (120yg/kg/min)
had a beneficial effect on lysosomal enzymes, but not on hemodynamic function.
A slightly beneficial effect on survival was observed (82).
Thus, it appears from the studies of infusion of PGs E and F and of the
precursor AA during hemorrhage that each of these may have a salutory effect.
All infusions were capable of improving survival in lethal hemorrhage models.
On the other hand, the small number of animals used in these studies of PG
infusions raises serious doubt concerning the validity of the conclusions
drawn from these experiments.

Moreover, it should be noted that infusions

were given intravenously in most of these studies.

Since PGs E and F are

rapidly inactivated by the pulmonary vascular bed in normal circumstances,
there is cause for concern that infused PG would be largely metabolized

.
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in one passage through the lung.

On the other hand, as was noted above, the

metabolism of primary PGs is apparently diminished during hemorrhage.

The

amount of PG reaching the tissues in these studies (91, 154, 155) remains,
therefore, unknown.

The salutory effects of intraventricular PGE-j (211)

are comparatively minor and based on small numbers of animals.

AA, however,

is not affected adversely by passage through the pulmonary vascular bed (122)
and infusion of this compound during hemorrhage has been shown to be bene¬
ficial

(82).

This study cannot, however, distinguish which PG, whether a

primary PG (PGE or PGF) or a different PG, such as PGor TXA^, is bene¬
ficial during hemorrhage.

The above study is also supported by the finding

that total inhibition of PG synthesis by indomethacin is detrimental to or¬
gan function, such as kidney function (110, 111).
The studies described above indicate that arterial PGE^ levels are
elevated during hemorrhage and that associated with this increase was an
equivocal decrease in the ability of the pulmonary bed to inactivate circu¬
lating PGE.

The effect of PG synthesis blockade appears to be deleterious to

renal autoregulation, but no convincing effect on survival following hemor¬
rhage has been documented.

Finally, PG infusion during hemorrhage appears

to be beneficial, although little data is available regarding this aspect.

2.

Sepsis, Endotoxin Shock, and Prostaglandins
A large number of studies have been conducted to determine possible

roles for PGs in sepsis and sepsis-like states.
only one has used an animal model of bacteremia.

Of these many studies,
The remainder have all

used endotoxin, generally derived from Escherichia coli, although not necessa¬
rily from the same bacterial strain.

The endotoxin has, however, generally

been obtained from a common commmercial source.

.
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The single study of PGs in bacteremia was reported by Culp and cog
workers (46).

These investigators injected an LD-jqq dose of

col i, 4x10

organisms/kg of the enteropathic Dunwald strain, into anesthetized dogs and
observed a slow decrease in MAP to 45% of baseline values 1 hour after in¬
jection.

This effect persisted for the remaining three hours during which

the animals were observed and was associated with an increase in portal vein
pressure.

Pretreatment with indomethacin (20 mg/kg) or with other anti¬

inflammatory drugs (flufenamate, aminopyrine, and phenylbutazone) was found
to reduce the decrease in MAP and to improve survival.

The increased sur¬

vival reported, however, was not statistically significant in this study.
Prostaglandin levels during endotoxin shock have been the subject of a
number of reported studies.

Anderson et. a]_.

(12, 14), using RIA, measured

plasma levels of PGE and PGF 60 to 90 minutes after administration of endo¬
toxin.

They found PGE levels to increase from baseline 0.27 ng/ml to 6.1

ng/ml after 60 minutes and PGF concentrations to increase from 1 to 5 ng/ml
during endotoxemia.

Collier and co-workers (43) also found increased PGE£

levels in renal vein plasma during endotoxemia, as measured by bioassay
(to 2-8 ng/ml).

Kessler et al_.

(138) also found a vasodilating substance

in plasma following injection of endotoxin, which they inferred to be a PG.
Herman and Vane (113), using bioassay, reported increased renal vein PGE

2

and PGF^ following endotoxin administration, but found no increases in ar¬
terial, inferior vena cava, or femoral vein samples.
(124) obtained similar results.

Isakson and associates

Most recently, Fletcher and Ramwell demon¬

strated increased PGF^ (by RIA) in arterial and venous plasma of dogs (73)
and baboons (76) durinq endotoxemia.

They obtained PGF0

2a

levels in the

rangeof 100 pg/ml which increased to 400 pg/ml following E. coli endotoxin in¬
jection.

Administration of endotoxin to calves has been demonstrated to pro¬

duce increased pulmonary synthesis of PGF^,
tension (13, 15).
calf (5).

associated with pulmonary hyper¬

This finding is strikingly similar to anaphylaxis in the

Thus, a number of investigations have documented increase in PGE

levels (12, 14, 43, 113, 124) or in PGF2
following endotoxin administration.

levels (12-15, 73, 76, 113, 124)

There is, however, disagreement about

both the site of synthesis and the absolute levels of PGE.

Moreover, these

results have not been substantiated using GC-MS.
There has been only one study reported concerning in vivo metabolism
of PGs during endotoxemia.

Fletcher and Ramwell

(74) demonstrated increas¬

ed PG extraction ratios in baboon subjected to LD-jqq endotoxin.
of investigators have described in vitro data.

Two groups

Nakano and Prancan (187)

noted a marked diminution of PG metabolism by cell free systems derived from
rat liver and kidney following

an LD^q dose of endotoxin.

Subsequently,

they have reported (210) a decreased activity of PGDH in rat lung homogenates
following administration of a large dose of endotoxin (10 mg/kg).
findings, however ,

These

are contrary to those reported by Flynn and Lefer (81).

These investigators found no decrease in PG metabolic capabilities of rab¬
bit lung, liver, and kidney homogenates following endotoxin administration.
Thus, the question whether pulmonary metabolism of PGs during endotoxemia is
altered remains unanswered.
The question of the role of PGs during endotoxemia has interested a
number of investigators.

The approach used by many has been the use of

pharmacologic blockade of PG synthesis using indomethacin or aspirin.

.
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Erdos and colleagues (63, 116) found that both indomethacin and aspirin
blocked both the acute (2 minutes after injection) systemic hypotension and
pulmonary hypertension and also the delayed hemodynamic and metabolic altera
tions of endotoxemia in dogs.

The hemodynamic parameters which were observ¬

ed were systemic pressure, cardiac output, and portal vein pressure; the
metabolic parameter was arterial pH.
subsequently confirmed by Hall et al_.

These early studies in dogs have been
(104), Herman and Vane (113), Hilton

and Wells (115), and the group of Fletcher et al.

(72, 73).

In addition,

the latter two groups reported increased survival, as assessed by survival
time (115) and by increase in number of survivors from 46% to 100% following
treatment with indomethacin or aspirin (72).
The existence of marked species variations in response to aspirin has
been documented.

Hall et_ aj_.

(104) showed that both cats and sheep had more

striking acute hemodynamic alterations, which were aspirin sensitive.

These

investigators also found, however, that the delayed effects of hypotension
and acidosis were both of smaller magnitude and less responsive to aspirin
in cats and sheep than in dogs.

Greenway and Murphy (66) also described

marked acute physiologic alterations in cats given Salmonella enteriditis
endotoxin, which they found to be eradicated by aspirin pretreatment.
Parratt and Sturgess demonstrated amelioration of acute changes in endotoxemic cats using indomethacin, meclofenamate, and flubiprofen (203-206).
They also reported improved cardiovascular function and diminished acidosis
following treatment with these three structurally different PG synthesis in¬
hibitors, but did not obtain statistically significant increases in survival
Reichgott and Engelman (214) found that indomethacin did not alter survival

■
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in rats subjected to endotoxin shock.

Studies in baboons have revealed that

indomethacin or aspirin improved acute hemodynamics in animals given a mas¬
sive dose of endotoxin (LD-jqq, 20 mg/kg, ref. 76).

Baboons subjected to a

less severe endotoxemia (LD^q) showed no benefit of indomethacin on delayed
hemodynamic parameters, but did show an increase in survival rate following
indomethacin treatment (75).
The effects of PG synthesis blockade on organ function in endotoxin
shock has been studied only by Isakson and co-workers (124).

They found im¬

provement in systemic blood pressure and decreased renin output following in¬
domethacin pretreatment of canine endotoxemia.

These authors did not, how¬

ever, comment whether renal function or blood flow was altered.
From these studies of PG synthesis blockade in endotoxin shock, three
conclusions may be drawn:

1.) administration of large doses of endotoxin

causes a species specific anaphylactic reaction, the hemodynamic element of
which is partly dependent on PG synthesis;

2.) the delayed effects of endo¬

toxin, i.e., hypotension, may be improved by treatment with PG synthesis
blockers, but effects on survival are minimal;

3.) species variations con¬

found efforts to construct a unified pathophysiologic theory of sepsis.
Data concerning the therapeutic use of PG infusion during endotoxin
shock have been similarly inconclusive.

Raflo and associates (93, 212) re¬

ported improved hemodynamics and increased survival of dogs which received
intravenous infusions of PGE-, or PGF0
Sorrells et aj_.

followina endotoxin administration.

(243) noted hemodynamic improvements in dogs pretreated with

9.5 yg PGE-j infused over 10 minutes prior to endotoxin injection.

The num¬

bers of animals used in these studies, however, were small and it is there¬
fore, unclear whether or not these results may be regarded as significant.

‘
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Moveover, other investigators have failed to observe improvements in
survival or in physiologic parameters following PG infusion during endotoxin
shock.

They have used several different infusion schedules:

PGE-|

(1 yg/kg/min

for 2 hours) in dogs given an LDgg injection of endotoxin (165); using PGE-j
(2 yg/kg/min for 4 hours) in dogs (235); or using PGA^, PGE^, or PGFg^
(1 yg/kg/min) following LD^q endotoxin administration to rabbits (79).

Of

note, however, is Flynn's observation (79) that arachadonic acid infusion
(15 yg/kg/min) did improve survival following endotoxin shock.

This suggests

that a different PG, such as an endoperoxide, PGIgj or TXAg, may play a pro¬
tective role during endotoxemia.

A1ternatively, this finding might suggest

that the availability of AA for PG synthesis is a limiting factor, so that in¬
fusion of AA allows tissues to synthesize PGs as required.
Thus, endotoxin shock studies reveal a confusing picture in relation to
PGs.

The body of evidence suggests that levels of PGE and PGF^ are altered

during endotoxemia; yet whether this represents increased synthesis or de¬
creased degradation is not known.

Most studies using PG synthesis inhibitors

have implied that PGs play a role in the acute hypersensitivity reaction to
endotoxin administration; the effects of PGs during endotoxic shock are, how¬
ever, unclear.

Studies intended to define a role of PGs by infusion of dif¬

ferent PGs have yielded contradictory information, although the most recent
of these studies implies that PGs play a protective role in an indeterminate
manner.
Finally, as has been noted earlier, the significance of endotoxin shock
in understanding the pathophysiology of clinical sepsis is unclear.

Certain¬

ly the acute hemodynamics of endotoxin injection in laboratory animals.

■
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using overwhelming doses of endotoxin, has little to do with the clinical
observations.

Thus, the role of PGs in sepsis remains unknown.

26.

AIM OF THE PRESENT INVESTIGATION
Despite the large number of investigations into the possible roles of
prostaglandins in hemorrhage and endotoxemia, there is still much debate on
that subject.

Studies on PGs during hemorrhage and endotoxin shock have not

provided consistent results, as has been described in the previous sections,
and frequently results have been questioned on the basis of the small num¬
ber of animals used.

For example, although arterial PGE^ has been reported

by many authors to be elevated during hemorrhage, there is still no clear in¬
dication whether altered pulmonary metabolism of circulating PGs contributes
to this increase in arterial concentrations.

There is little agreement on

the effect of PG synthesis inhibition or of PG infusion during hemorrhage.
Studies in endotoxin shock have shown repeatedly that PG synthesis inhibition
abolishes the acute effects of endotoxin administration; the effect of this
intervention (PG blockade) is unclear in the later stages of endotoxin shock.
One of the sources of the

disagreements concerning PG roles in the

altered circulatory states of hemorrhage and sepsis may be that previous
studies have usually used large animals, particularly dogs.

Use of large

animal models, however, may introduce variables, such as species differences,
uncertain diets prior to studies, and so on.

The use of small animals, such

as rats, may allow more control of these variables,

since genetically identi¬

cal animals, of the same age and sex, and on the same diet, are available in
large numbers without undue expense.

Thus, a number of biological variables

are minimized, and numbers for adequate statistical analysis are available.
Therefore, it would be constructive to carry out investigation concerning
the role of PGs during hemorrhage and sepsis using a small rodent, such as

.
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the rat, for which reliable models are well established.

The following

questions might be then addressed:
1. )

Are prostaglandin levels altered during hemorrhage, as assessed by
readily available methods, such as RIA?

2. )

Is the capacity of the pulmonary vascular bed to metabolize PGs altered
during hemorrhage, and how might this affect circulating levels of PGs?

3. )

Does PG synthesis inhibition by indomethacin affect the outcome follow¬
ing hemorrhage?

4. )

Does infusion of PGE2 following inhibition of endogenous PG synthesis
by indomethacin benefit survival following hemorrhage?

5. )

Does PG synthesis inhibition affect the outcome following various stages
of sepsis, and if so, does this direct to further studies?

28.

MATERIALS AND METHODS

Animal Models
A.

Hemorrhage Model
1.

For Measurement of Plasma Prostaglandin Levels

Albino male rats of the Holtzman strain (Charles River, Wilmington,
Mass.) weighing 300 to 375 gm were fasted for 16 hours prior to experiments,
but allowed water ad libitum.

Under light ether anesthesia, cannulae were

inserted into the right femoral artery, right femoral vein, and right sub¬
clavian artery, using PE-50 polyethylene tubing.

For studies of plasma PG

levels only, the renal vein was also cannulated. Using electrocautery, a
2 cm midline abdominal incision was made and the peritoneal cavity opened.
The right iliofemoral vein was isolated and a silastic cannula (O.D., 0.037")
was inserted and directed so that its tip lay in the left renal vein ap¬
proximately 6 mm from the hi 1 urn.

The silastic cannula was brought out

through the skin via a stab wound in the flank and the abdomen was closed.
Each of the above cannulae was flushed with 250 U sodium heparin.

The fe¬

moral artery cannula was connected to a 1.75 m length of PE-50 tubing pre¬
viously calibrated in mm Hg to allow constant monitoring of mean arterial
pressure (MAP).
lowed to awaken.

The animals were restrained in a supine position and al¬
Ether was used only during cannulation, thus avoiding any

metabolic or hemorrhagic alterations which might be incurred by circulating
anesthetic.
Following equilibration of blood pressure (MAP>100 mm Hg) hemorrhage
was initiated.

Initial

(control) blood samples (1 to 1.5 cc) were taken

from the subclavian artery, renal vein, and femoral vein.

The subclavian

'
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artery cannula was then connected to a heparinized lOcc glass syringe which
served as a blood reservoir and blood withdrawn so that MAP fell to 40 mm Hg
within 800 seconds.

Animals were maintained at this level of hypotension by

further withdrawal or return of shed blood.

Thirty or 60 minutes following

initiation of hemorrhage a second set of samples (0.8 to 1.5 cc) was with¬
drawn from the above cannulae.
2.

For Studies of Pulmonary Metabolism of Prostaglandins

In another set of experiments designed to assess pulmonary metabolism
of PGE2 during hemorrhage the above procedure was slightly modified.

Rats

were used in groups of four and PE-50 tubing cannulae were inserted into
the right femoral artery and vein and into the right subclavian artery.
subclavian cannula was lodged as close as possible to the aortic arch.

The
Nine

animals were subjected to hemorrhagic hypotension for 75 minutes as described
above.

The control group were prepared in exactly the same manner, i.e.,

cannulated and allowed to awaken, but were not bled.

Labeled

(5, 6, 8,

11, 12, 14, 15-^H-PGE^, specific activity 130.0 mCi/ymol), which had been
rechromatographed on silicic acid columns and dissolved on 100% ethanol, was
injected into the femoral vein and flushed with 0.5 cc saline.

The amount

of labeled PGE^ used was approximately 1.25 yCi in 0.2 cc ethanol.

Immediate-

following injection blood was withdrawn from the subclavian artery cannula
for 20 seconds (1 to 2 cc) and the sample quickly injected in 8 cc ice-chilled
redistilled ethyl acetate.

Thereafter rapid thoracotomy was performed and a

small piece of lung tissue taken from the right lower lobe using stainless
steel tongs which were pre-cooled in liquid nitrogen.

30.

3.

For Studies of Survival following Pharmacologic Manipulations

The hemorrhage model was modified for a set of experiments designed to
assess survival following pharmacologic manipulations of PGs during hemor¬
rhage.

Animals were cannulated (right femoral artery and vein and left

femoral artery), connected to a manometer as previously described, restrained
in a supine position, and allowed to awaken.

Animals were studied in groups

of four so that animals with and without indomethacin and/or PGE^ treatment
during hemorrhage could be run concurrently.

In the first set of rats the

survival following hemorrhage in animals treated with indomethacin was com¬
pared with survival in animals receiving vehicle alone.

Fifteen to 30 min¬

utes prior to bleeding animals were pretreated with indomethacin (5 mg/kg);
control animals received the equivalent volume of vehicle (20 mM phosphate
buffered saline, pH 7.6).

In the second set of experiments survival follow¬

ing hemorrhage was compared between two groups:
methacin pretreatment and PGE

2

alone.

those which received indo¬

infusion; and those which received vehicle

One group of animals served as indomethacin-controls.

These animals

received indomethacin pretreatment and infusion, but were not hemorrhaged.
Fifteen to 30 minutes following pretreatment with indomethacin (5 mg/kg)
or buffer, hemorrhage was initiated by bleeding the animals into a 10 cc
heparinized glass syringe.

Simultaneously all animals received one of the

following four solutions, infused via a Harvard infusion pump at a rate of
0.01 ml/min during the entire 75 minute course of hemorrhage:
Control 1 (vehicle only)
Indomethacin treatment

20 mM phosphate buffered saline
3.5 mg/kg/hr indo. in buffered saline

Control 2 (vehicles only)
Indo. + PGE treatment

3% absolute ethanol in saline
0.1 yg/kg/min PGE in saline.

2

Aliquots of PGE

2

2

were made up just prior to use and the infusion solution was

■

replaced with freshly diluted solution after 45 minutes to assure infusion
of chemically unaltered PGE .
2

The corresponding control group received

3%

ethanol to match the ethanol concentration given to PGE^-infused rats.
Animals were bled to 40 mm Hg and maintained for 75 minutes at that
hypotension.

After 75 minutes the remaining shed blood was reinfused and

the cannulae were removed.

Animals were returned to their cages and allowed

food and water ad 1ibiturn.

Survival was assessed over a period of 48 hours.

Animals which died were examined at autopsy for evidence of gastrointestinal
bleeding.
4,

For Studies of Blood Gases during Hemorrhage

A small number of animals were used to determine arterial blood gases
during hemorrhage.

Animals were prepared as for survival studies and pre¬

treated with indomethacin (5 mg/kg) or vehicle.

Infusion of indomethacin

or buffer as described above was started at the initiation of hemorrhage.
An initial sample of blood (1.5 cc) was withdrawn from the femoral artery
for blood gas analysis.

After maintenance of 40 mm Hg hypotension for 75

minutes, a second arterial blood sample (1.5 cc) was withdrawn and analyzed
for blood gases.

B.

Sepsis model
Sepsis was induced by cecal ligation and puncture according to the

model previously described (272).

Albino male Holtzman rats (300 to 375 gm)

were fasted for 24 hours prior to the study.

Animals were studied in groups

of four so that control and treatment data could be obtained simultaneously.
Following the initiation of food deprivation, animals were given indometha¬
cin (1 mg/kg) dissolved in olive oil or the equivalent volume of oil alone
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subcutaneously twice a day for a total of three days.

Twenty-four hours

after the initiation of fasting and treatment, animals were given a bolus
of indomethacin (4 mg/kg) or the equivalent volume of phosphate buffered
saline intraperitoneally.

After thirty minutes animals were anesthetized

lightly and a 2 cm midline abdominal incision made.

The cecum was isolated

and ligated with a 5-0 silk without producing intestinal obstruction.

The

cecum was punctured twice with an 18 gauge needle, placed back into the
peritoneal cavity, and the abdominal wound closed in layers.

Animals were

then given normal saline (30 cc/kg) subcutaneously and returned to their
cages.

Food and water was withheld for an additional 48 hours.

Ten or sixteen hours later (corresponding to early or late sepsis,
respectively), animals were again anesthetized and PE-50 cannulae in¬
serted into the right femoral artery and vein.

The arterial line was con¬

nected to a manometer and only animals with MAP>_90 mm Hg were used and in¬
cluded in the study.

The abdomen was then reopened and the cecum excised.

The peritoneal cavity was thoroughly lavaged with warm saline and the abdomi¬
nal incision closed.

Following removal of the cecum, animals were treated with

indomethacin (6.7 mg/kg) or buffer intravenously and given intravenous saline
(15 cc/kg)
cages.

over 3 to 5 minutes.

Thereafter, rats were returned to their

Food and water were still withheld.

Over the succeeding 36 hours

animals were given saline subcutaneously, as well as subcutaneous indometha¬
cin or oil vehicle, according to the schedule shown in Figure 2.
after, animals were allowed food and water ad libitum.
over the interval of five days following cecum removal.

There¬

Survival was assessed
Animals which died

were examined for evidence of gastrointestinal hemorrhage.

•

A.

FIGURE 2
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PROTOCOLS FOR SEPSIS SURVIVAL STUDIES

Day

Time

Early Sepsis

1

4:00 pm

0

8:00 am
4:30 pm

Late Sepsis

-Indo 1 mg/kg or oil SQ-Food withheldIndo 1 mg/kg or oil SQ
Indo 4 mg/kg or vehicle IP

Indo 1 mg/kg or oil SQ

Cecal ligation and Puncture
Saline 30 cc/kg SQ
Indo 1 mg/kg or oil SQ

5:00 pm

1

10:30 pm

Indo 4 mg/kg or vehicle IP

11:00 pm

Cecal Ligation and Puncture
Saline 30/cc/kg SQ
Indo 1 mg/kg or oil SQ

9:00 am

-Monitor MAP-Excision of Cecum-Lavage of PeritoneumIndo 6.7 mg/kq or vehicle IV
-Saline 12 cc/kg IV— Indo 1 mg/kg or oil SQ—

4:00 pm

-Saline 15 cc/kg SQ---—Indo 1 mg/kg or oil SQ

2

8:30 am

-Saline 22.5 cc/kg SQIndo 1 mg/kg or oil SO

6

9:00 am

Legend:

Assess Survival

Indo = Indomethacin
Vehicle = 20 mM phosphate buffered saline
SQ = subcutaneous
IP = intraperitoneally
IV = intravenously

'

'
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Analytic Procedures
A.

Preparation of Samples for Assay of Prostaglandins
The blood samples were placed immediately on ice and centrifuged,

usually within 5 minutes,at 4° C. in a Beckman J-21B centrifuge.
ma supernatant was removed and frozen at -80° C.

The plas¬

Plasma samples were

assayed for PGs within 10 days.

B.

Extraction and Measurement of Plasma Prostaglandins
Measurement of plasma PGs was done by radioimmunoassay (RIA) according

to the method of Jaffe and Behrman(126).
The frozen samples were thawed to room temperature and PGs extracted
with redistilled ethyl acetate at a pH of approximately 4.5.
centrifuged at 3000 rpm for 10 minutes at 4° C.

and the supernatant re¬

moved and evaporated under air at room temperature.
solved in benzene:ethyl acetate:methanol

Samples were

The residue was dis¬

(60:40:2).

A column chromatography procedure was used to separate PGE and PGFifteen cm glass burets containing 0.5 gm silicic acid were set up.

Sam¬

ples were placed onto the columns and elution of PGs carried out using benzene:ethyl acetate:methanol mixtures of increasing methanol concentration.
This procedure has been shown previously to give excellent separation of
PGs (35).
Radioimmunoassay was carried out using standard techniques (126).
PGE and

assays were done simultaneously, using the fractions separated

by chromatography.

Column eluents were evaporated at room temperature, the

PGF fraction under air and the PGE fraction under nitrogen.
were redissolved in absolute ethanol.

The residues

Aliquots of 0.05, 0.2, and 0.4 cc

■-
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were placed in test tubes and evaporated under air (PGF) or nitrogen (PGE)
at room temperature.

Anti-sera were obtained from goats which had been in¬

jected with PGE or PGF conjugated to bovine serum albumen by carbodiimide.
Antisera and labelled PGE or PGF a were added to assay tubes.
2

Known standards

of each PG were run in triplicate concurrently, using concentrations of 0.1
to 20 ng/ml.

Mixtures of antiserum, labelled PG, and samples/standards were

allowed to equilibrate at 4° C. over a two hour interval.

Antigen-antibody

complexes were precipated using charcoal-coated dextran and samples centri¬
fuged at 2500 rpm for 5 minutes at 4° C.

Supernatant free PGs were decanted

into scintillation vials and 10 cc Formula-963 scintillation fluid added.
Samples were counted for 10 minutes on a Packard Tri-carb liquid scintilla¬
tion counter.

Concentrations of unlabelled PG in rat plasma samples were

calculated from the curves of known standards.

C.

Thin Layer Chromatographic Separation of Prostaglandin Metabolites
A number of investigators have used several thin layer chromatographic

systems (TLC) to separate the primary pulmonary metabolic degradation pro¬
ducts of the PGs (10, 99, 213, 244).

For the in vivo pulmonary metabolism

study described below, it was essential to be able to separate quantitative¬
ly the PGE

2

metabolites.

To determine the best system for separation four

solvent systems were tested.
Prostaglandin E

2

and its three principal pulmonary metabolites,

13,14-dihydro-PGE2, 15-keto-PGE and 13,14-dihydro,15-keto-PGE2, were
dissolved in absolute ethanol and stored under nitrogen at -80° C.

TLC

of these four compounds was performed using 250 y Silica Gel G plates.
Along a line 1 cm from the lower edge of the plate 300-500 yg of each

.
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compound was spotted.

The plates were dried under room air.

Four solvent

systems were made up:
1.

Ethyl acetate:water;2,2,4-trimethyTpentane,;acetic acid 110:100:20:1

2.

Benzene:dioxane:acetic acid 20:10:1

3.

Benzene:dioxane:acetic acid 66:33:1

4.

Benzene:dioxane:acetic acid 40:10:1.

Solvents were placed in a chromatography tank to a depth of approximately 0.5
cm and the plate placed into the tank.

Plates were left in the solvent un¬

til the solvent edge had run 12-13 cm, which required 70-90 minutes.

Fol¬

lowing this, the plates were removed, air dried, sprayed with 3I phosphomolybdic acid, and heated gently on a warm hot plate for 10 minutes.
corresponding to each compound were identified and

Spots

values calculated as

(distance traveled by compound) / (distance traveled by solvent front).

D.

Preparation of Blood and Lung Samples for Metabolism Studies.
Blood samples, which had been injected into ice-chilled ethyl acetate

immediately after withdrawal, were centrifuged at 4° C. at 6000 rpm for 15
minutes in a Bedkman J-21B Centrifuge and

the supernatant removed.

To

assess recovery of labeled PGE^ an aliquot of 0.1 cc was taken for counting.
The remainder of the sample was evaporated under

nitrogen at room tempera¬

ture and redissolved in 0.2 cc absolute ethanol.
Lung samples were stored at -32° C. until a sufficient number were
collected within 24 hours.

Samples were weighed and homogenized quickly in

1 cc trichloracetic acid (10%)-HC1

(0.1 N).

chilled redistilled ethyl acetate was added.
6000 rpm for 15 minutes at 4° C.

To each homogenate 8 cc iceSamples were centrifuged at

and an aliquot of 0.1 cc taken to test

.
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recovery.

The remainder was evaporated under nitrogen at room temperature

and redissolved in 0.2 cc absolute ethanol.
Recovery samples were evaporated under room air at room temperature and
the residue dissolved in 0.1 cc absolute ethanol.

To this solution 10 cc

Formula-963 scintillation fluid was added and the recovery samples counted
for 10 minutes on a Packard Tricarb Liquid Scintillation Counter.

E.

Separation of Labeled Prostaglandins for Metabolism Studies
Ethanol dissolved residues (from extraction of plasma containing labeled

PGE^ and metabolites) were subjected to TLC, using solvent system 4 and 250 y
Silica Gel G plates.

Mixtures of standards containing 350 yg of each

metabolite and 350 yg of PGE

2

were spotted at two points on each plate 1 cm

from the lower edge of the plate.

Four samples were spotted in a volume of

0.15 cc each to run in parallel with the known standards.
under air.

Spots were dried

Plates were run as described above, air dried at room tempera¬

ture, and the two sections of the plate containing standards sprayed with
3% phosphomolybdic acid

Upon gentle heating the standards were identified

and the areas on the plate containing labeled compound which corresponded
with standard compounds thereby identified.

These areas were removed end

eluted into scintillation vials using methanol, which was evaporated under
air and the residue redissolved in 0.1 cc absolute ethanol.

To each vial

10 cc Formula-963 was added and samples counted on a Packard Tri-Carb Liquid
Scintillation Counter for 10 minutes.
To assess the purity of the injected tritiated PGE^, as well as to check
the validity ot separation achieved by TLC, a small aliquot of each lot of
3
H-PGE

2

was also subjected to TLC.

Except wnere otherwise noted, all values

■

it
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presented have been corrected for background and for initial impurity.
Fractional amounts of each metabolite have been calculated as M./(Mg + M-j +
Mg + Mg), where Mg_g represent the corrected cpm of native PGEg, 13,14-dihydro-PGEg, 15-keto-PGEg, and 13,14-dihydro,15-keto-PGEg, respectively.

F.

Blood Gas Measurement
Samples of arterial blood for blood gas analysis were taken for immedi¬

ate analysis on an IL Blood Gas Analyzer (Model 213).

Values reported are

the mean of three determinations on each sample.

Statistical Methods
All data have been analyzed according to standard statistical technique.
Statistical comparison of mean values has been carried out using a two-tailed
Student's t test.
square analysis.

Survival data have been compared using a two-tailed ChiDifferences are considered statistically significant for

values of p<0.05.

Materials
Unlabelled prostaglandin Eg and its three metabolites were the generous
gift of Dr. John Pike (Upjohn Company, Kalamazoo, Mich.).

Tritiated PGEg

(5,6,8,11,12,14,15- H-PGEg) was purchased from New England Nuclear (Boston,
Mass.).

Tritiated PGFg^ (5,6,8,11,12,14,15-^H-PGFg) for RIA was also ob¬

tained from New England Nuclear.

Indomethacin was the generous gift of

Merck, Sharp, and Dohme (Rahway, N.J.) and Dr. H.R. Behrman.
Tubing for cannulation consisted of PE-50 polyethylene tubing (Clay
Adams, Parsippany, N.J.) and Silastic tubing (Dow Corning, Midland, Mich.).
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Equipment for TLC included Silica Gel G plates, obtained from New Eng¬
land Nuclear, as was Formula-963 scintillation fluid.
analyses were of analytic grade or better.
prior to its use.

All reagents used in

Ethyl acetate was redistilled
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RESULTS

Plasma Prostaglandin Levels during Hemorrhage
Plasma concentrations of PGE and of PGF0

obtained from the subclavian

artery, femoral vein, and from the renal vein of 10 rats both at the initi¬
ation of hemorrhage and 30 or 60 minutes after the initiation of hemorrhage
are shown in Tables 1 and 2.

It is apparent from these tables that PG levels

vary dramatically, irrespective of source and of time obtained in relation to
hemorrhage.

The initial PGE levels in renal vein plasma varied from 0.59 to

26.3 ng/ml; in femoral vein from 1.5 to 61.5 ng/ml; and in subclavian artery
from 0.76 to 51.3 ng/ml.

Similar variations in PG levels were observed in

samples taken from these sites following 30 or 60 minutes of hemorrhage.

Like¬

wise, values for PGF^ concentration in plasma varied markedly.
Mean PGE and PGF0

levels are presented in Table 3.

It is clear from

this table that there are no significant increases or decreases in either
PGE or PGF^ levels at various intervals during hemorrhage.

Although mean

PG levels at 60 minutes are lower than mean initial values in both subclavian
artery and femoral vein samples, these decreases are misleading, as is evi¬
dent from values reported in Tables 1 and 2.
mals reported are small.

Moreover, the numbers of ani¬

The absence of significant changes is not surprising

in the face of the large variations in individual values.
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TABLE 1

PLASMA PROSTAGLANDIN E2 LEVELS DURING HEMORRHAGE
PGE (ng/ml) and relative PGE
60 min.

Animal

Source

Initial PGE

30 min.

1

SA
FV
RV

25.3
bl .5*
24.3

14.4 (0.57)
15.1 (0.25)

2

SA
FV
RV

26.6
19.2
5.2

6.5 (0.22)
10.8 (0.56)
10.8 (2.01)

SA
FV
RV

51.3*
21.1
22.4

10.1

3

4

SA
FV
RV

5.95
8.48
5.89

4.90 (0.84)
7.50 (0.88)
11.34 (1.92)

5

SA
FV
RV

6.68
7.24
5.80

6.74 (1.01)
9.08 (1.25)
8.17 (1.41)

6

SA
FV

4.98
5.77

7.48 (1.57)
6.83 (1.18)

7

FV
RV

1 .55
1.60

1.66 (1.07)
2.57 (1.61)

SA
FV
RV

0.74
4.13
10.93

0.70 (0.95)
0.94 (0.23)
4.40 (0.40)

SA
FV

3.44
8.68

2.02 (0.59)

9
10

RV

0.59

1.43 (2.42)

8

*

-

(0.20)
-

-

Values determined from only one aliquot, rather than as the mean
of three.
Measurement of PGE-equivalent by RIA of plasma samples obtained from
subclavian artery (SA), femoral vein (FV), and renal vein (RV) at dif¬
ferent times in relation to hemorrhage.
Relative values are ratios of
PGE levels during shock divided by initial values and are given in pa¬
rentheses.
See Methods for further details.
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TABLE 2

PLASMA PROSTAGLANDIN F

2a

LEVELS DURING HEMORRHAGE

PGF0_. (ng/ml) and relative PGF0„.
_ Oi

-E_U,

Animal

Source

Initial PGF

l—
2 cx

30 min

SA
FV
RV

17.6
12.0
12.0

14.9 (0.85)
10.6 (0.88)

2

SA
FV
RV

13.0
8.8
1.5

11.0 (0.85)
6.4 (0.73)
4.7 (3.18)

SA
FV
RV

12.5
9.8
5.3

4.6 (0.37)

3

1

60 min

-

-

-

FV
RV

0.89
0.73

0.88 (0.99)
0.96 (1.32)

SA
FV
RV

0.68
0.93
1 .26

0.61 (0.90)
0.69 (0.74)
1.73 (1.37)

9

SA
FV

0.78
1.12

1.30 (1.67)
1.14 (1.02)

10

RV

0.71

0.69 (0.97)

7

8

PIasma PGF2a levels as measured by RIA from samples obtained from subcl avian artery (SA) , femoral vein (FV), and renal vein (RV) at different times in relation to hemorrhage.
Relative values are ratios of
PGF2a levels during hemorrhage divided by initial values and are pre¬
sented in parentheses.
For details, see Methods.
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TABLE 3

MEAN PLASMA PROSTAGLANDIN LEVELS DURING HEMORRHAGE

PG In nq/ml
PG

60 min

Source

Initial

30 min

E

SA
FV
RV

10.4 ± 4.1
11.0 ± 2.1
5.8 ± 1.5

7.3 ± 3.6
12.9 ± 2.1
6.1 ± 4.7

5.0 ± 1.5
5.2 ± 1.6
6.8 ± 1.9

Foca

SA
FV
RV

8.6 ± 3.5
4.6 ± 2.4
1.1 ± 0.2

10.2 ± 3.0
6.1 ± 2.7
2.7 ± 2.0

1.0 ± 0.4
0.8 ± 0.1
1.4 ± 0.3

Plasma prostaglandin E and F2a levels as determined by RIA of sam¬
ples obtained from subclavian artery (SA), femoral vein (FV), and
renal vein (RV).
Values presented are averaged data from 7 to 10
rats subjected to hemorrhage for 30 or 60 minutes.
Values given
are mean ± SEM.
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Thin Layer Chromatography of Prostaglandin Eq and its Pulmonary Metabolites
Four solvent systems were tested using PGE2 and its three major pulmonary
metabolites on silica gel G plates.

values are presented in Table 4.

On

the basis of this data solvent system 4 was chosen for use in studies using
labeled PGE2> since it gave complete separation of all four compounds with
zones between neighboring compounds.

This system, therefore, offered the

possibility of minimizing erroneous identification of metabolites.
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TABLE 4

THIN LAYER CHROMATOGRAPHY OF PROSTAGLANDIN E2
AND ITS PULMONARY METABOLITES ON SILICA GEL G
USING FOUR SOLVENT SYSTEMS

Solvent System
1.

Ethyl acetate:water:
isooctane:acetic acid
110:100:20:10

PGE:.

M1

M^

Mi

0.82

0.76

0.78

0.84

2.

Benzene:dioxane:
acetic acid 20:10:1

0.41
0.47

0.600.62

0.65
0.72

0.730.76

3.

Benzene:dioxane:
acetic acid 66:33:1

0.340.43

0.490.52

0.670.72

0.700.73

4.

Benzene:dioxane:
acetic acid 40:10:1

0.150.21

0.260.28

0.420.47

0.490.54

Thiri layer chromatographic separation of known :standard PGE2 andI its
three primary metabolites on 250 y Silica Gel G using different sol vent systems.
Compounds are:
PGE2
Mx
M2
M3

=
=
=
=

Prostaglandin E2
13,14-dihydro-PGE2
15-keto-PGE2
13,14-dihydro,15-keto-PGE2
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Pulmonary Metabolism of Prostaglandin Eg during Hemorrhage
Prior to infusion of labelled PGE , its purity was assessed by TLC.

The

2

first lot, which was used in 12 of the 15 experimental animals, showed 93.2%
PGEg with the predominant impurity being M-j

(13,14-dihydro-PGEg, 5.5%).

The

second lot was shown to contain 84.5% ^H-PGEg, 6.7% M-j , 3.0% Mg (15-keto-PGEg),
and 5.8% Mg (13,14-dihydro,15-keto-PGEg).

The impurities do not necessarily

represent PGE metabolites per se, but might be impurities which simply have
the same

as the metabolites.

The results presented below, however, have

been calculated with these impurities taken into account.
Studies of metabolites in arterial blood showed a significant increase
in the amount of unmetabolized PGEg after 75 minutes of hemorrhage as com¬
pared with control animals.

Fractional counts of PGEg and its three metabo¬

lites are given in Table 5 and mean values in arterial blood and lung tissue
are given in Table 6.

The increase in unmetabolized PGEg from 20.7% to

57.4% is statistically significant (t= 3.06, p<0.01).

Most of the decreased

metabolism was accounted for by decreased oxidation to Mg (from 38.9% to 17.3%,
t=2.44, p<0.05) and, to a lesser degree, to Mg (35.9% to 19.5%, t=1.34,
p<0.10).
There was virtually no difference in relative amounts of metabolites in
lung tissue, as is shown in Table 6.

Recovery of label in the lung tissue

was greater, however, in hemorrhaged animals (32.9 + 5.6 cpm/mg lung tissue)
than in controls (5.2 + 1.2 cpm/mg lung tissue).
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TABLE 5

IN VIVO METABOLISM OF PROSTAGLANDIN E2 DURING HEMORRHAGE

Fractional concentrations of PGEq and Metabolites

M

PGE2
CONTROL

2

M
"3

0.204
0.162
0.469
0.122
0.191
0.093

0.109
0.060
0.090
0.040
0.007
0.041

0.483
0.748
0.248
0.150
0.423
0.263

0.204
0.030
0.193
0.688
0.379
0.602

0.450
0.925
0.409
0.314
0.465
0.469
0.517
0.663
0.957

0.074
0.039
0.085
0.076
0.075
0.098
0.027
0.025
0.022

0.358
0.023
0.182
0.428
0.078
0.127
0.203
0.143
0.010

0..118
0..008
0..324
0.,182
0..382
0..306

FOLLOWING 75 MIN
HEMORRHAGE

0..253
0..169
0.,011

Relative in vivo concentrations of PGE2 and its three primary metabo¬
lites in arterial blood 5 to 20 seconds following bolus intravenous in¬
jection of labelled PGE2 in 9 animals subjected to hemorrhage for 75
minutes and 6 unhemorrhaged control animals.
Numbers represent ratio
of counts associated with each metabolite to total counts obtained, fol¬
lowing separation of compounds by TLC.
Compounds:
PGE2
Mi
M2
M3

=
=
=
=

Prostaglandin E2
13,14-dihydro-PGE2
15-keto-PGE2
13,14-dihydro,15-keto-PGE2
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TABLE 6

AVERAGE IN VIVO METABOLISM OF PROSTAGLANDIN E2 DURING HEMORRHAGE

Fractional Concentration of PGEq and Metabolites
BLOOD

LUNG

Compound

Control

Hemorrhaged

Control

Hemorrhaged

pge2

0.207 + 0.055

0.574 + 0.090*

0.267

0.284

0.058 + 0.015

0.058 + 0.010

0.204

0.202

0.389 + 0.088

0.173 + 0.043**

0.207

0.176

0.349 + 0.121

0.195 + 0.019

0.322

0.336

mi
M2
M3
*
**

p < O.Ol compared with control
p < 0.05 compared with control

Average relative concentration of PGE2 and its metabolites in
arterial blood and lung tissue following injection of labelled
PGE2 into 9 rats subjected to hemorrhage for 75 minutes and 6
unhemorrhaged rats.
Numbers represent ratios of counts asso¬
ciated with each metabolite to total counts measured, following
separation of compounds by TLC.
Values here represent mean +
SEM.
PGE2
M2
M2
M3

=
=
=
=

Prostaglandin E2
13,14-dihydro-PGE2
15-keto-PGE2
13,14-dihydro,15-keto-PGE2

..

4
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Survival following Hemorrhage
A total of 92 rats were used for this study.

Of these, 72 rats are in¬

cluded in the calculation of survival rates following hemorrhage.
tional

An addi¬

16 were excluded because of technical failures, such as excessive

blood loss during decannulation (n=5) or because they died during the hemor¬
rhage procedure (n=ll).

All of the four unhemorrhaged indomethacin controls

survived.
As shown in Table 7, the survival rate following hemorrhage in control
rats

(receiving buffer as pretreatment and infusion) was 68.8% (11/16).

The

survival rate in animals which received indomethacin pretreatment and infusion
was 29.8% (5/17), which is significantly less than controls (x' =5.10, p<.025).
Eight animals which were receiving indomethacin died before the completion
of the 75 minute hemorrhage period.

These animals did not appear to be sub¬

jected to more severe hypotensive stress than other animals.

Since no con¬

trol animals died during the hemorrhage interval and death during hemorrhage
has been extremely rare in previous studies in this laboratory, the death of
8 indomethacin treated animals reported above would appear to be related to
the adverse effect of indomethacin.

Indeed, the survival rate of animals

treated with indomethacin, including the 8 which died during hemorrhage was
20% (5/25), which is significantly less than controls (x2=9.74 5 p<0.001).
There were no differences in the severity of hemorrhage in the groups
of animals which did or did not receive indomethacin, as shown by shed volume
(10.7 vs 10.3 cc) or amount of shed blood returned during 75 minutes to main¬
tain the animals at 40 mm Hg (29.2% vs 24.5% of total amount shed).

Autopsy

of all dead animals did not reveal any evidence of gastrointestinal hemor¬
rhage.

'
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In another set of experiments PGE

2

was infused during hemorrhage into

animals which had previously received the PG synthesis blocker indomethacin.
The purpose of this experiment was to determine whether selective replace¬
ment of PGE

2

PGE

2

during hemorrhage would be beneficial and whether blockade of

synthesis was responsible for the decreased survival in animals treat¬

ed with indomethacin.

The control animals in this group received buffer pre¬

treatment and a 3% ethanol infusion to correspond with the ethanol concentra¬
tion in treated animals.

The survival rate of these control animals was

55.6% (5/9) which is not significantly different from control animals which
did not receive ethanol.

Animals given indomethacin pretreatment to block

de novo PG synthesis and selective infusion of PGE

2

at peak physiologic rates

had a survival rate of 42.1% (8/19), which is not significantly different
from controls or from animals which received indomethacin alone.

Three ani¬

mals which received indomethacin and PGE2 died during the 75 minute hemor¬
rhage period.

If these animals are included in the survival data, total

survival was 36.4% (18/22), which is significantly different from controls
(x2=3..88. p<0.05) but not from animals treated with indomethacin alone.
results indicate that infusion of PGE

2

These

alone following blockade of endogenous

PG production does not have beneficial effects on survival following hemorrhage.

■
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TABLE 7

SURVIVAL FOLLOWING HEMORRHAGE

Died during
Hemorrhage

Overall

% Survival

Survived

Died

% Survival

11

5

68.8

0

68.8

Indomethacin pretreatment
and infusion

5

12

29.4a

8

20.0b

Buffer pretreatment and
3% ethanol infusion

5

4

55.6

0

55.6

Indomethacin pretreatment
and PGE2 infusion

8

11

42.1

3

36.4C

Treatment
Buffer pretreatment
and infusion

a.
b.
c.

p < 0.025 compared with control.
p < 0.001 compared with control.
p < 0.05 compared with control.

Survival data in 71 rats subjected to 75 minutes of hemorrhagic hypoten¬
sion (MAP = 40 mm Hg) using different treatment protocols.
Animals were
pretreated with indomethacin (5 mg/kg) or buffer vehicle intravenously
15-30 minutes prior to hemorrhage and infused at 0.01 ml/min with buffer,
indomethacin (3.5 mg/kg/hr), 3% ethanol in saline, or prostaglandin E2
(100 ng/kg/min) throughout the 75 minute period of hemorrhage.
Survival
was assessed at 48 hours after hemorrhage.
Overall percent of survival
indicates rate of survival including animals which died during the hemor¬
rhage procedure.

.
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Blood Gas Analysis during Hemorrhage in Relation to Indomethacin
Out of the four animals used in this study, one served as a control and
was subjected to hemorrhage following buffer pretreatment and with buffer
infusion.

The other three rats were pretreated with indomethacin and in¬

fused with indomethacin during hemorrhage.
Table 8.

Blood gases are presented in

There are no differences between the arterial blood gas values of

the two groups of animals studied.

.
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TABLE 8

BLOOD GAS STUDIES DURING HEMORRHAGE

Animal

1

Treatment

Indomethacin

Initial

\
P

128

108

19

16

7.54

7.28

80

120

28

20

7.55

7.40

98

120

36

23

7.48

7.34

102

116

28

20

7.52

7.34

85

120

33

20

7.55

7.26

rco2
pH

%
2

Indomethacin

After 75 min
Hemorrhage

Parameter

p
rC02

PH

P°2

3

Indomethacin

P

kC02
pH

Mean of
above 3

Indomethacin

%
PC02
pH

P°2

4

Buffer

pco2
pH

Comparison of arterial blood gas values in 3 rats given indomethacin
(5 mg/kg) pretreatment and an infusion of indomethacin ([3.5 mg/kg/hr)
with 1 rat given buffer in equal volumes throughout the 75 minutes of
hemorrhage.
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Survival Following Sepsis
Sepsis was produced by cecal ligation and puncture followed by excision
of the necrotic septic focus after 10 hours (early sepsis) or 16 hours (late
sepsis).
As shown in Table 9, the survival rate of late septic rats which were
not treated with indomethacin was 30.8% (4/13).

This is consistent with the

survival rate reported previously using this model

(272).

Late septic rats

which were treated with indomethacin had a survival rate of 23.1% (3/13).
There is, thus, no significant difference in survival in late septic rats be¬
tween the animals which did receive indomethacin and those which did not.
The survival rate of early septic rats not treated with indomethacin
was 83.3% (10/12).

Treatment with indomethacin in another group of early

septic rats resulted in a survival rate of 25% (3/12), which is significantly
less than the control group (x2=8.22, p<0.005).
Autopsy of dead animals showed no evidence of gastrointestinal bleeding
in any animals.

Diarrhea, a commonly observed phenomenon in septic rats,

appeared to be decreased in rats treated with indomethacin.

■

■
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TABLE 9

SURVIVAL FOLLOWING SEPSIS

Survived

Dead

10

2

83.3

3

9

25.0 *

Control

4

9

30.8

Indomethacin
Treatment

3

10

23.1

%

Survival

EARLY SEPSIS

Control
Indomethacin
Treatment

LATE SEPSIS

*

p<0.005 compared with control.

Five day survival data in 50 rats subjected to sepsis in¬
duced by cecal ligation and puncture.
After 10 or 15
hours (early or late sepsis) the cecum was removed. Ani¬
mals received indomethacin (1 mg/kg) or oil vehicle twice
daily for 3 days beginning 24 hours prior to ligation
plus indomethacin (4 mg/kg) or bugger intraperitoneally
30 minutes prior to ligation plus indomethacin (5 mg/kg)
or buffer intravenously following excision of the cecum.
For further details, see "Methods".

'
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DISCUSSION

1.

Hemorrhage and Prostaglandins
In attempting to assess possible roles for PGs during hemorrhage, a

series of experiments were undertaken using a model of hemorrhagic hypo¬
tension in the rat (40).
clude:

The specific studies which were conducted in¬

1.) measurement of plasma PG levels at various time intervals af¬

ter the initiation of hemorrhage;

2.) determination of in vivo single pass

pulmonary PGE^ metabolism after 75 minutes of hemorrhage; and

3.) assess¬

ment of survival after 75 minute hemorrhage in rats treated with indomethacin and with indomethacin-PGE2 combination.

The results of these experiments

indicate that PGs probably play an important protective role during hemor¬
rhagic hypotension.

A.

Measurement of Plasma Prostaglandin Levels during Hemorrhage
In one set of experiments the rat model was adapted for measurement of

plasma PGs in blood samples from the subclavian artery, femoral vein, and
renal vein, using RIA.

The result of this investigation was that no altera¬

tions in the levels of PGE or of PGF0
minutes of hemorrhage.

could be demonstrated after 30 or 60

From these data (presented in Tables 1-3) the fol¬

lowing conclusions could be drawn:

1.) there was a large variation in PG

levels during hemorrhage irrespective of time or site of sampling; and
2. ) that there were no patterns either in absolute mean values or in the
relative concentrations of the PGs during hemorrhage.

Thus, it appears that

no conclusions regarding the roles of PG during hemorrhage in the rat can be
drawn on the basis of these data.
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The large variation in both PGE (0.53 to 61.3 ng/ml) and PGF a (0.61 to
2

17.6 ng/ml) is evident from Tables 1 and 2.

It is also apparent from these

Tables that PG levels in the first animals studied were higher than in sub¬
sequent animals.

Although data were collected from three groups of animals

studied on separate occasions (i.e., animals 1-3, 4-6, and 7-10), no changes
in techniques or reagents were made.

Moreover, RIA of a standard plasma pool

was carried out concurrently with sample assays and revealed only small vari¬
ations, indicating that the variations in the levels of experimental samples
were not introduced by human error.

There are several other possible ex¬

planations for the large variation in PG levels which was observed.
factors include:

1.) uncontrolled and variable synthesis of PGs by plasma

elements during or immediately after withdrawal;
by freezing and thawing;

2.) alterations induced

3.) errors introduced by measuring small amounts

of PG in very small volumes of plasma;
nique of RIA;

These

4.) variation inherent in the tech¬

5.) spurious PG synthesis associated with surgical trauma or

with animal struggling.

Each of these possibilities is discussed below.

It is possible that synthesis of PGs occurred in sample blood or plas¬
ma after withdrawal, thereby altering values obtained by RIA.

Platelets are

known to produce PGsin large quantities (88) and might be the source of spuri¬
ous PG synthesis.

This might have occurred in spite of heparinization and

rapid centrifugation at 4° C,

Thus, this is certainly a possibility.

Freezing and thawing has been reported to cause alterations in measured
PGs (126), presumably by destruction of PGs.

In general, however, altera¬

tions have not been documented until 3 weeks of freezing.

'
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In the studies of PG levels reported here, the volumes of plasma which
were used for RIA were very small

(0.35 to 0.80 ml), due to the limitations

inherent in the use of a small animal model, particularly for hemorrhage
studies.

The measurement of small amounts of PG (with attendant error)

when divided by small volumes (also with associated error) yielded values
that may be inaccurate.

Indeed, previous studies of PG levels in human

plasma have suggested that for reliable RIA a minimum of 10 ml of plasma
is required (53).

Obviously, it is not possible to obtain such a volume

from a 350 g rat before or during hemorrhage.

Previous canine studies of

plasma PG levels during hemorrhage, using RIA (80, 132), have not specified
plasma volumes used for assay.

It would have been possible, however, to use

volumes of 5-10 cc in these studies.
The recent review by Granstrom (98) concerning RIA of PGs in plasma
has indicated that this method is indeed fraught with difficulties.

Errone¬

ous values have frequently been obtained by RIA of plasma, although the tech¬
nique of RIA is itself relatively reliable.

The cause of the difficulties

in plasma RIA is not known, and whether or not it is non-PG plasma elements
which interfere with the assay has not been determined.

The problems associ¬

ated with RIA of plasma samples may be appreciated by noting that previous
investigators studying PGE levels during hemorrhage in dogs have de¬
scribed baseline PGE levels as 340 and 450 pg/ml
RIA.

(80, 132) when measured by

Other investigators using different techniques have reported baseline

values one-tenth of that value (less than 20 pg/ml by bioassay, ref. 129,
and less than 50 pg/ml by GC-MS, ref. 84).

Thus, it is possible that values

reported in this study are falsely elevated in part because of the short¬
comings of RIA of plasma PGs.

The review of Granstrom (y8), however, was

.

•
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published a few months after most of the plasma PG studies reported here were
conducted.
Finally, the trauma of cannulation or, perhaps, withdrawal of blood might
have caused release of PGs from tissues or vessels.

In addition, animals in

this experiment were awake at the time of the hemorrhage.

This required re¬

straining the animals in a supine position, which caused them to struggle.

The

animals' struggling might have led to increased PG synthesis either because of
increased sympathetic output or increased muscular activity, both of which are
associated with increased PG synthesis (109, 139).

There are, however, two

arguments against these possible explanations of spurious PG synthesis.

First,

these effects might be expected to be observed primarily in the initial samples,
since animals struggled most at that time.

The variations in PGE and PGF^

levels were, on the other hand, also large after 30 or 60 minutes of hemor¬
rhage, indicating that struggling or initial surgical trauma are unlikely ex¬
planations of the variations in PG levels.

The second argument is that the ini¬

tial samples were withdrawn from unhemorrhaged rats, in which the ability of the
pulmonary bed to metabolize circulating PG levels would suggest that factors
other than initial surgical trauma or awake restraint were probably responsible
for the large variations in PG levels.

The most likely factors, therefore, are

the use of small plasma volumes, the problems associated with RIA determination
of plasma PGs, and the possibility of platelet synthesis of PGs in samples af¬
ter withdrawal from animals.
The absence of changes in plasma PG levels during hemorrhage stems in
large part from the large variations in measured PG levels.

The observed

scatter of data makes conclusions based on mean values tenuous.

Even using
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relative PG levels (concentrations after 30 or 60 minutes of hemorrhage divi¬
ded by initial values), no patterns are observable.
either alterations in rat plasma PG levels

do

This suggests that

not occur during hemorrhage

or that these changes are masked by the wide range in individual values.
In summary, the attempt to ascertain whether PGs play a role in hemor¬
rhage by direct measurement of rat plasma PGE and PGF2a levels during hemor¬
rhage, using RIA, did not yield meaningful results.

Large variations

in PG levels in samples taken before and during hemorrhage were observed,
thus creating difficulty in assessing whether or not alterations in plasma
PG levels occur during such conditions.

The principal causes of the varia¬

tions in PG levels appear to be small sample size, use of RIA on plasma sam¬
ples, and possible spurious synthesis of PGs after withdrawal by blood or
plasma constituents.

B.

Pulmonary Metabolism of Prostaglandins during Hemorrhage
In order to study pulmonary metabolism of PGs for comparison of meta¬

bolic capability during hemorrhage with control values, the method of intra¬
venous injection of tritiated PGE^ and collection of arterial blood was used,
similar to that used by Hammond et al.

(106).

Data from control animals

indicate that rats were able to metabolize 79% of circulating PGE2 in a sin¬
gle pass through the lung.

This value is in agreement with values obtained

in humans (106), demonstrating the reliability of this technique in the rat
model.
The results presented here indicate that hemorrhagic hypotension for
75 minutes in the rat caused a marked decrease in in vivo single pass meta¬
bolism of PGE2 from 79.3% to 42.6%.

There was also significant decrease in

»*>

the formation of the major metabolic product, 15-keto-PGE2 (38.9% to 17.3%
of recovered radioactivity), and a smaller decrease in the formation of the
metabolite 13,14-dihydro,15-keto-PGE2 during hemorrhage, and particularly
implies a diminution in the activity of 15-hydroxy-PG dehydrogenase, the
intracellular enzyme responsible for oxidation of the 15-hydroxyl moiety
(226).
The substantial reduction in single pass metabolism of PGE

2

during

hemorrhage is in agreement with studies of several previous investigators in
dogs (30, 86, 128) and in baboons (74).

These four studies have determined

relative arterial and venous PG concentrations and found that the ratio of
arterial to venous PG concentrations increased during hemorrhage.

This find¬

ing, as Frolich pointed out (86), does not exclude the possibility of pul¬
monary production of PGs.

Indeed, Frolich's findings suggest that pulmonary

production of PGs is increased markedly during hemorrhage.

There has been

only one report which suggests that venous PGE reaches the arterial circula¬
tion in greater amounts during hemorrhage (117).

These investigators found

that hemorrhage led to an increase in arterial PGE^ levels following intra¬
venous injection of the PG, as measured by the crude bioassay of increased
platelet anti-aggregatory activity.
Flynn and Lefer (81) reported that hemorrhage does not alter the capa¬
city of rabbit lung homogenates to metabolize PGE.

It is conceivable, how¬

ever, that the metabolic activity was altered during the process of isola¬
tion and homogenization, thus reconciling their in vitro observations with
the in vivo studies noted above (30, 74, 86, 117, 128).
apparent difference might represent a species difference.

A1ternatively, this
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The more likely explanation of the seeming contradiction in in vivo
and in vitro results is that the reportedly intact intracellular metabolic
system may not come into contact with the circulating PGs.
possible mechanisms which could account for this:

There are two

a right-to-left vascular

shunt which would bypass the lung; and vascular endothelial cell membrane
dysfunction.
The alterations in blood flow in the lung during hemorrhage may include
the development of venous admixture, i.e., right-to-left shunting
Such shunts would

(249).

bypass the pulmonary vascular bed, or at least the small

vessels, thereby allowing circulating PGE to pass into the arterial circula¬
tion without having traversed the pulmonary bed.

Thus, the PGs would not

come into contact with the endothelial cells and could not be metabolized.
Against this possibility is the data from blood gas studies which demonstrated
the absense of hypoxemia after 75 minutes of hemorrhagic hypotension.

This

observation, however, does not refute the hypothesis of vascular shunting,
but suggests rather that such shunting is not occurring to a major degree at
that point in hemorrhage.

Nonetheless, it would be instructive to determine

the precise amount of shunting after 75 minutes of hemorrhage, since this would
help establish the contribution of such shunting to the observed decrease in
metabolism of circulating PGs during hemorrhage.

This implies, then, that

other possibilities must be considered as well.
The alternative explanation is that the pulmonary vascular endothelium
is less capable of transporting the PG into the cell where normal amounts
of PGDH are thought to be present (81).

Since membrane transport is an

energy requiring process (26), one might speculate that ischemic cell injury
could cause a decrease in the ability of endothelial cells to provide energy

■-
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for this process.

This is consistent with the alterations in other membrane

mediated effects seen during hemorrhage (40).

On the other hand, previous

studies have indicated that lung cellular energy levels and active trans¬
port are not altered during hemorrhage (232).

The precise mechanism of di¬

minished PGE^ metabolism by the lung remains, therefore, unclear.
In comparison with the marked decrease in metabolism of PGE£ and in ar¬
terial blood samples following 75 minutes of hemorrhage, analysis of lung tis¬
sue samples showed no difference in relative amounts of PGE£ and metabolites
between control and hemorrhaged animals (see Table 6).

The

possible explan¬

ations for the differences between lung tissue and arterial blood metabolism
include:

1.) that the numbers of counts recovered from lung tissue unhemor¬

rhaged animals were very small, so that ratios of metabolites in these sam¬
ples are subject to large error;

2.) the increased radioactivity which was

associated with the M, fraction could have been due to a different PGE0
metabolite altogether; and

3.) the delay of approximately 25 seconds be¬

tween arterial blood withdrawal and removal of lung tissue makes comparison
of relative metabolite concentrations between blood and tissue questionable.
The total number of counts per milligram of tissue was, however, increased
during hemorrhage.

This increased radioactivity could have been present

either intracellularly or extracel1ularly, although the data reported here
does not allow such a distinction.

Nonetheless, explanations for increased

radioactivity in hemorrhaged animals can be introduced for both locations.
If the counts were extracellular, this would be consistent with diminished
cardiac output during hemorrhage so that clearance of PGs would be prolonged
and the labelled PGs could not be entirely washed out into the systemic
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circulation.

If, on the other hand, the counts were retained intracel1ularly,

this would imply that transport of metabolites out of the cell might be the
rate limiting step.

Which of these factors predominates during hemorrhage

is not known.
From the data reported here it is clear that the rat is normally able
to metabolize approximately 80% of circulating PGE^ in a single passage
through the pulmonary vascular bed.

Single pass PGE

2

metabolism decreases

to approximately 43% during hemorrhage, thereby doubling the arterial level
of PGE^ of venous origin.

The precise cause of the decreased metabolism

during hemorrhage may encompass several factors, such as:

a decrease in the

amount of PGDH, although in vitro data does not support this hypothesis (81);
right-to-left vascular shunting which bypasses the pulmonary circulation;
and a diminished ability of pulmonary endothelial cells to transport PGs
into the intracellular site of PGDH.

At present, it is not possibile to

distinguish the contributions of these hypothetical factors to the decrease
in in vivo single pass PGE

2

C.

metabolism.

Survival Studies following Hemorrhage
The results presented in this study indicate that pretreatment with and

infusion of indomethacin during hemorrhage caused a significant decrease in
survival following 75 minutes of hemorrhage in rats.

The survival rate de¬

creased from 68.8% to 29.4% (p < 0.05) in animals which were treated with
indomethacin in doses which would give virtually complete inhibition of
endogenous PG synthesis (77, 221).

Hence, these results suggest that PG

synthesis plays a protective role during hemorrhage in the rat.

'
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The mechanism of this protection is unclear.
reported, such as that of Jakschik e^ al_.

Canine studies previously

(29), have demonstrated that indo-

methacin administration causes an increase in systemic blood pressure and
in blood loss in animals.

In the present study, however, no alterations in

blood pressure, blood loss, or reuptake were noted in indomethacin treated
animals.

This suggests that the effects of indomethacin were on organ

perfusion or were due to local effects rather than systemic effects.
The effects of PG synthesis blockade on organ perfusion and function
has been studied by a number of groups of investigators.

Among these effects

is the finding that indomethacin causes decreased flow to vital organs (heart,
brain, gut and liver, kidney) during hemorrhage by increasing vascular re¬
sistance (150).

Since indomethacin is an effective blocker of PG synthesis,

this study (150) implies that PGs contribute to perfusion of vital organs du¬
ring hemorrhage.

Several studies on canine hemorrhagic hypotension have in

fact demonstrated that indomethacin blocks the vasodilation of the renal and
hepatic arteries which is induced by hemorrhage (23, 47, 87, 110, 111, 258).
That PGs are the responsible agents is suggested by the finding of increased
resistance in the renal vascular bed during hemorrhage when PGs were blocked
with other antagonists with inhibitory mechanisms different from indomethacin.
Thus, a number of organ function studies suggest that the protective effect
of PGs may be on organ perfusion.
The hypothesis that the protective effects of PGs relates to vasodilatory protection of perfusion of critical organs is attractive.

In the

rat, however, the renal vascular effects of some of the PGs are unlike those
in other species.
hances

In particular, PGE

2

is a renal vasoconstrictor and en¬

the effects of the renal sympathetics (57, 109).

In most other

<
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species the PG which opposses sympathetic activity has been identified as
PGE

2

(the effects of PG^ have not been described).

Thus, unless rat renal

sympathetic output leads to release of a different vasodilating PG, one
might expect that PG synthesis blockade would protect renal blood flow during
hemorrhage in the rat, precisely the opposite of the finding in dogs, as de¬
scribed above.

Given the deleterious effect of indomethacin on overall sur¬

vival in rats, the

notion that the mechanism of this diminution in survival

relates to organ blood flow is more difficult to accept.

It is possible,

on the other hand, that the other vital organ beds in the rat behave in a
manner similar to the canine renal bed and that the balance of effects, i.e.,
improvement following indomethacin in the rat kidney but worsening elsewhere,
leads to decreased survival.

Clearly this matter requires further investi¬

gation .
In light of the hypothesized maintenance of vital organ perfusion as a
mechanism of protection afforded by PGs during hemorrhage, one might consi¬
der the cause of death in the eight indomethacin treated rats which died sud¬
denly during the 75-minute hemorrhage interval.
associated with indomethacin treatment.

Their deaths were clearly

It is possible, for example, that

these eight died because of acute failure induced by impairment of flow to a
vital organ, secondary to PG synthesis inhibition by indomethacin.

This is,

however, purely speculative.
As a final consideration in the studies of indomethacin effect on sur¬
vival following hemorrhage, it ought to be pointed out that indomethacin has
other effects besides inhibition of PG synthesis (77).

Although doses used

would have inhibited PG synthesis completely (221), they would also have
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produced drug concentrations equivalent to those which inhibit PGDH and
phosphodiesterase in vitro.

Thus, before it is possible to conclude that the

deleterious effects of indomethacin treatment during hemorrhage are due to
PG synthesis inhibition, other PG inhibitors ought to be used (191).
Given that PG blockade is detrimental, the next logical question is
which of the PGs are the responsible protectors.

Indomethacin inhibition of

PG biosynthesis blocks production not only of primary PGs, but also of the
endoperoxides (PGG

2

and PGH^),

thromboxanes, and prostacyclin, through its

inhibitory effect on cyclooxygenase (Figure 1, step 2).

In attempting to

dissect out one part of this question, survival was assessed in animals
treated with a combination of indomethacin (to block production of endogenous
PG production) and PGE^ (infused at peak physiologic rates, 0.1 yg/kg/min).
The selective replacement of PGE

2

was found to be of no significant

benefit as assessed by survival following hemorrhage.

Although PGE

2

appears

to provide some benefit in that the survival rate in animals given indometha¬
cin plus PGE

2

was greater than that in animals given indomethacin alone, this

increase was not statistically significant.
sence of significant PGE

2

venous PG infusate.
the infused PGE

2

One possible cause of the ab¬

effect might be pulmonary metabolism of the intra¬

One might expect, however, that a significant amount of

would have reached the arterial bed, on the basis of the

pulmonary metabolism studies described above.

In addition, indomethacin pre¬

treatment might have limited PGDH activity, as has been reported in vitro
(77).

Thus, a significant amount of infused PGE

2

should have been able to

reach the arterial circulation to be distributed to tissues.
PGE

2

did not improve the survival rate, circulating PGE

2

Since infused

does not appear
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to be the sole responsible protective factor during hemorrhage.
potheses must, therefore, be considered.

Other hy¬

Prominent among these are:

that locally synthesized PGE£ is the responsible factor;
ferent PG (i.e., PGI^) is the responsible factor; and

1.)

2.) that a dif¬

3.) that the combined

effects of several different PGs are required for protection during hemor¬
rhage.
In summary, indomethacin treatment during hemorrhage led to increased
mortality, implying that PGs play a protective role during hemorrhagic hypo¬
tension.

D.

Circulating PGE

2

alone was not, however, the responsible factor.

Summary and Conclusions concerning Prostaglandins in Hemorrhage
The results and discussion above point out the fact that the studies

conducted to explore possible roles of PGs in hemorrhage have answered only
some questions and raised many more.

The evidence that PG synthesis blockade

was detrimental to survival following 75 minutes of hemorrhagic hypotension
in the rat suggests that PGs do, in fact, play a significant role in hemor¬
rhage.

Where, how, and when they do is unclear.

The use of the rat model has shown some distinct advantages, notably
ease of carrying out experimental protocols on large numbers of animals.
The opportunity of using large numbers of animals for further survival studies
suggests the possibility of dissecting the complex scheme of PGs and assessing
the role of each of several factors.

Thus, use of selective blockers or of

infusions of PGI^ and JXI\^ during hemorrhage might prove worthwhile.
A disadvantage of the rat model lies in the small plasma volume, limit¬
ing the accuracy of measurement of various humoral and local vasoactive sub¬
stances.

This is particularly true during hemorrhage.

The studies reported

'
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here have pointed out the pitfalls in measuring rat plasma PG levels by RIA
during hemorrhage.
Despite the lack of success in demonstrating alterations in plasma PG
levels during hemorrhage, the diminution of PG metabolism in vivo has been
established.

This finding is consistent both with pulmonary shunting and

with the alterations in other cellular and organelle functions during hemor¬
rhage.
Finally, the effect of indomethacin on survival suggests that PGs play
a protective role during hemorrhage.

The inability to reverse this detri¬

mental effect with PGE^ alone suggests several hypotheses, as discussed
above, which will require further investigations.

In particular, studies

directed toward understanding the role various PGs play in organ perfusion
during hemorrhage would appear to be essential.

2.

Sepsis and Prostaglandins
The results described above indicate that indomethacin treatment caused

a substantial decrease in the survival of animals following early sepsis,
but not following late sepsis.

The survival rate following early sepsis in

the indomethacin group was 25% as opposed to 83% in animals which received
vehicle alone (controls).

In contrast survival following late sepsis was

not significantly altered by indomethacin treatment (23% vs. 30% control).
This is the first demonstration that indomethacin treatment is deleterious
following experimental sepsis.

These results, thus, suggest:

sis is a complex and evolving process; and

1.) that sep¬

2.) that PGs probably play a

role in this pricess, but whether this role is primarily vascular or inflam¬
matory is not known.

• l ■>.
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The observation that sepsis is an evolving process is evidenced by the in¬
creased mortality of control animals in late sepsis as opposed to early sep¬
sis.

This data corresponds wi th earlier data from this laboratory which in¬

dicated that rats in the early septic phase have a hyperdynamic circulation
and are hyperglycemic.

In contrast, late septic animals

lar depression and hypoglycemia (41).

show

cardiovascu¬

Since the mortality rate of animals

following late sepsis was significantly more than following early sepsis,
this suggests that mortality varies inversely with cardiovascular status of
the animal.

This is precisely what has been observed in clinical settings

(189).
Related to this observation is the finding that indomethacin alters sur¬
vival following early sepsis but not late sepsis.

These results suggest that

PGs play a vital role in homeostasis during early sepsis and that factors
other than PG may play a more important role during late sepsis.

Certainly

the profound hypoglycemia and circulatory changes seen in late sepsis would
be expected to overshadow any more subtle hemodynamic alterations attributa¬
ble to the PGs.

Thus, PG synthesis blockade would not be expected to alter

survival following late sepsis and the results presented above support this
notion.
Since indomethacin, which blocks PG synthesis, affected the survival of
animals following early sepsis, it is essential to ascertain the precise role
PGs play during sepsis.

One possible role of PGs is that they may regulate

organ and local tissue perfusion analagous to their postulated role in hemor¬
rhage.

It is conceivable that indomethacin alters the hyperdynamic circula¬

tion of early sepsis and that this is detrimental.

As discussed above, how¬

ever, indomethacin may inhibit other enzymes (PGDH, phosphodiesterase) and

'
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neutrophil function (77).

Thus, the use of indomethacin alone does not

necessarily prove that PG synthesis inhibition is the only responsible fac¬
tor for increased mortality following indomethacin treatment.

In addition,

the PGs are believed to contribute actively to the inflammatory response
(119).

Thus, it is conceivable that the deleterious effects of indometha¬

cin following early sepsis could relate more to the modification or inhibi¬
tion of normal host defenses than to circulatory alterations.

The mechanism

of action of indomethacin could, therefore, be due to inhibition of PG re¬
lated changes in host defenses (119), to prevention of the capability of
bactericidal leukocytes to reach the site of infection (77), or to deleterious
circulatory alteration.

Clearly, this area requires further investigation.

To summarize, using a reliable model of sepsis in rats, the effects
of indomethacin treatment in both early and late sepsis have been studied.
The results presented indicate that indomethacin treatment following early
sepsis was deleterious, but did not alter the already high mortality of late
sepsis.

This implies that PGs play a significant role in sepsis, but that

their significance may be eclipsed by other factors as sepsis evolves.

It

is not clear whether the effects of PGs in early sepsis relate primarily to
vascular function or to the inflammatory reaction; this requires further
investigation.
Finally, the differences between sepsis and endotoxin shock are made
apparent from this study.

The clear demonstration of a deleterious effect

of indomethacin in early sepsis is in striking contrast to observations
during endotoxemia (63, 66, 72, 73, 75, 76, 104, 113, 115, 203-206, 214).
Indeed, most studies using endotoxin have found benefits of PG synthesis
inhibition, particularly related to the acute changes of systemic

'

72.

hypotension and pulmonary hypertension (63, 66, 72, 73, 76, 104, 113, 115,
116, 203-206).

Such changes are not, however, observed in sepsis.

altered state observed in late endotoxin shock appears, however,
lel that late sepsis, at least in some respects.
sed in both conditions, and mortality is high.

The
to paral¬

The circulation is depres¬
Consistent with these ob¬

servations is the finding that indomethacin does not produce dramatic ef¬
fects on survival following either late sepsis or endotoxin shock.

On ac¬

count of the hemodynamic similarities between endotoxin shock and late sep¬
sis, it is conceivable that endotoxin contributes to the conditions found
in sepsis.

To conclude, however, that the pathophysiology of late sepsis

is identical to that of early sepsis would not appear to be justified, on
the basis of the different hemodynamic patterns (45) and response to indo¬
methacin.

Sepsis seems to be a pathophysiologic process involving a num¬

ber of factors.

These include the host defense, circulatory, and endocrine-

metabolic systems, as well as a number of hormones related to these sys¬
tems, including PGs.

Further studies using a sepsis model, such as has

been described here, will contribute to the understanding of the complex
process of sepsis.

73.

APPENDIX
The Prostaglandins

The following pages comprise a brief compendium of the salient aspects
of PG physiology as gleaned from a number of review articles which are cited
and to which the reader is directed for further and fuller description.

In

addition there is a recent monograph (119) and three reviews of the clinical
aspects of PGs (135, 183, 184).

A.

Biochemistry (see ref. 11, 120, 156, 229-231, 264).

The PGs are a set

of 20 carbon chain fatty acids containing one to three double bonds and a
five carbon ring (Cg-C^)-

They are subdivided into three series, corres¬

ponding to the number of double bonds, and into several classes, according
to the structure and substitution on the ring.

Figure 1 shows the structures

and synthetic pathways of the most common series, the 2 series, as well as
the related thromboxanes, and the metabolic degradation products.

The pre¬

cursors for PG synthesis are essential unsaturated fatty acids, such as arachadonic acid (AA), which form part of the cell membrane phospholipids, from
which they are released by the action of phospholipase A^.
affected by many factors, among which Ca

2+

and cAMP

This enzyme is

have been implicated.

The conditions which lead to release of AA and subsequent PG synthesis in¬
clude mechanical stimulation, anoxia, ischemia, anaphylaxis, embolization,
and probably several others (262).

Free AA is then transformed to the short¬

lived endoperoxide PGG^ by the enzyme cyclooxgenase (also called PG synthe¬
tase, EC 1.14.99.1), which is localized on the inner leaflet of cell mem¬
brane bilayers. . PGG^ then undergoes further transformation to a thromboxane
(TXA^), prostacyclin (PGI^), or a primary prostaglandin (PGEg or PG F^^) -

The
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enzymes responsible for these reactions are tissue-specific (e.g., platelets
make thromboxanes almost exclusively, whereas vascular endothelium makes none
under normal circumstances).
The PGs, however, have short half-lives in plasma, ranging from 30
seconds for TXA^ to several minutes for PGs E , F^, and I^.
2

Furthermore,

the primary PGs (E and F) disappear rapidly from the circulation (67); in
particular, they disappear during passage through the pulmonary circulation.
This has been documented in cats (48), dogs (217), guinea pigs (4), rabbits
(117), rats (202), and humans during cardiac catheterization (95) and open
heart surgery (106).

That lungs metabolize the PGs is consistent with the

observation that the pulmonary vasculature metabolizes many other vasoactive
compounds (19, 89, 227, 270).

Specifically, metabolism by the vascular endo¬

thelium is seen to be energy dependent (26), carrier mediated (27), and anionic
(28), implying intracel1ular metabolism of PGs.
been identified and purified (226).

The responsible enzymes have

The most important of these for the pri¬

mary PGs is 15-hydroxy PG dehydrogenase (PGDH, EC 1.1.1.141), which reduces
the 15-hydroxyl moiety to a keto group, thereby diminishing substantially the
activity of the PG.

Less important is PG A13 reductase which reduces the 13,14

double bond, rendering the PG inactive.

The presence of these enzymes has

been demonstrated in a number of tissues (2) and in vivo studies have been
conducted to substantiate in vitro results (180, 181, 186, 187).

More recent

studies on PG metabolism have established that the turnover of PGDH is very
rapid (29).

PGDH can be decreased by such factors as oxygen toxicity (61)

and increased by others such as pregnancy and progesterone (59).
To summarize, the PGs are synthesized intracellularly in response to a
number of stimuli by well established pathways.

They are inactivated rapidly
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in plasma and by the pulmonary vasculature.

B.

Cardiovascular Effects (see ref. 114, 148, 182, 185, 222, 265).

fects of PGs on the cardiovascular system are manifold.
and PGI^ are vasodilators and PGF

2

The ef¬

In general, PGE

2

and TXA£ are vasoconstrictors.

In both

pairs, the latter is more effective.
The cardiac effects (190, 242, 261) include:

vasodilation of the coro¬

nary bed by PGE^ and PGI^ (195) and constriction by PGF a and TXA
2

2

(251);

negative inotropic effects by PGE-j and E^ (142, 199, but also see 247); arrhythmogenic potential of PGF^^ (130, 141); and opposing anti-arrhythmic ac¬
tivity of the PGEs (133, 135, 157, 279).

The identity of the PGs primarily

responsible for control of the coronary bed is still being debated, through
current evidence favors PGI^ with a minor role ascribed to PGE .
2

The pulmonary vascular bed is not only responsible for metabolism of
circulating primary PGs but is also controlled by the PGs (269).

PGE-j dimin¬

ishes vascular tone by relaxation of smooth muscle (134), whereas PGF a causes
2

increased pulmonary artery pressure.

Infusion of arachadonic acid also pro¬

duces pulmonary hypertension (273), as does hypoxia and anaphylaxis; all of
these may be inhibited by PG synthesis blockade.

Patency of the neonatal

ductus arteriosus appears to be dependent on vasodilatory PGs (245).
Similar effects of PGs E0 and F0
c.

la

have been observed in the mesenteric

(171, 238), hepatic (215), skeletal muscular (171), and cutaneous vessels
(219).

Thromboxane ^ has been demonstrated to be a potent cerebral vaso¬

constrictor (62) and constricts peripheral vessels as well

(68).

These ef¬

fects are not surprising in view of the demonstration that vascular smooth
muscle is nearly universally relaxes by PGE

2

and contracted by PGF^^ (9).
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C.

Renal Effects

(16, 57, 70, 147, 168, 280).

five aspects of renal function:

PGs have been implicated in

distribution of intrarenal blood flow, regu¬

lation of systemic blood pressure, control of renin release, effects on tubu¬
lar function, and mediation of erythropoietin stimulation.
Flow in intrarenal vessels, as in most of the microvasculature, is af¬
fected by PGs.

PGs are synthetized in the medulla (112), but exhibit their

major distributional effect in promotion of flow to the cortex (22) by vaso¬
dilation.

This effect appears to be primarily reactive; i.e., they probably

do not control basal resistance, but are synthesized in conditions of altered
flow (200).

It should be noted that PGE^ has been found to be a vasoconstric¬

tor in the rat kidney.

However, whether PGI^ or PGE

2

is the major dilator is

not known (nor are the effects of PGin the rat renal bed).
The initial description of "medullin," a renal hypotensive lipid, promo¬
ted investigation into possible roles for PGs in opposing systemic hyper¬
tension (263).

Subsequent work indicates that the PGs may participate as

intermediates for other humoral substances and as intrinsic renal vasodilators
rather than as circulating hormones.

PGE

2

(or PG^) may exhibit effects

through diuresis accountable to renal vasodilation

(18), as well as through

control of renin.
The mechanism of renin release is still unclear.

As demonstrated by

indomethacin blockade of PG synthesis, renin release is dependent on PGs (277),
a finding supported by the demonstration that indomethacin inhibition of renin
release be overcome by infusion of PGE2-

The most recent suggestion (196) is

that PGs and catecholamines can independently stimulate renin release via sepa¬
rate receptors.

.

.
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The effects of renal PGs on fluid and electrolyte balance is also the
subject of continuing debate (16, 57, 166, 168, 256).

PGE

appears to func¬

2

tion as a natriuretic, perhaps on the basis of its vasodilatory capacity.
PGF a has been reported to conserve sodium.
2

lates that PGs E

2

One current theory (168) postu¬

and F a control sodium excretion, and they in turn are con¬
2

trolled through kinin effects on 9-ketoreductase (the enzyme which converts
PGE

2

to PGF a).
2

In addition, PGE

2

is reported to be an antagonist of anti¬

diuretic hormone (ADH), through actions on cAMP (57, 201).
ies of PG action in the kidney have been proposed, but no

Thus, many theor
unifying hypothe¬

sis has been postulated as yet.
Evidence for a role of PGs in erythropoietin stimulation has been pre¬
sented (101).

Further substantiation, however, is required.

In summary, the most important functions of PGs in the kidney are re¬
active.

They are synthesized in response to hemodynamic and hypoxic insults

In addition, they appear to mediate effects of some hormones (ADH, kinins).

D.

Pulmonary Effects (see ref. 65, 121, 163, 164, 228, 237).

As described

previously, the pulmonary vascular bed both plays an important role in PG
metabolism and is controlled by PGs.

PGs are also capable of producing ef¬

fects on airway smooth muscle analogous to effects observed on vascular
smooth muscle; viz., PGE

2

is a potent bronchodilator and PGF ais the most

potent bronchoconstrictor yet found.

2

The lung additionally functions as an

active secretor of PGs, particularly during hypoxia and anaphylaxis, suggest
ing that PGs may play a role in control of ventilation-perfusion matching.

E.

Gastrointestinal Effects (see ref. 52, 216).

The PGs are known to have

striking effects on gastrointestinal smooth muscle, PGE

2

being a prominent
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and potent stimulus to contraction of longitudinal smooth muscle and relaxer
of circular smooth muscle.
duction of PGs.

PGE

2

Cholera toxin diarrhea has been linked to pro¬

has also been found to possess the capacity to protect

against ulcer formation.

Correspondingly, PG inhibitors have long been asso¬

ciated with ulcer production.

Current theory holds that PGE£, through cAMP,

both inhibits histamine stimulated H+ release and itself leads to secretion
of the gastrointestinal polysaccharides, glycosaminoglycans.

F.

Endocrine Effects.

Most of the work on the endocrine effects of PGs have

centered around either reproductive roles of PGs or the interactions of PGs
with cAMP.

Infusion of PGE-j and PGE^ have, in addition, been reported to

cause increased plasma glucose by means of glucagon stimulation and inhibition
of glucose related insulin secretion (207, 218, 225).

Conversely, aspirin

blockade of PG synthesis is related to diminished glucose levels, especially
in diabetics, although the mechanism is unclear (173).

G.

Nervous System Effects (see ref. 32, 85, 109, 159).

The effects of PGs

on the nervous system fall into two classes, central and autonomic.

The cen¬

tral effects include a putative role in fever (66) and effects on neurotrans¬
mission (86).

More important are the peripheral autonomic effects.

hances cholinergic transmission (105).

Adrenergic transmission, however, is

inhibited prejunctionally by PGs, presumably by PGE£.
nism is interference with the movement of Ca
coupling,but this is speculative.

PGE en¬

2+

The postulated mecha-

in stimulation-contraction

Rat renal sympathetic nerves differ from

other species in that PGE^ enhances sympathetic effects.

In all other cir¬

cumstances, however, PGs again appear to subserve the function of maintenance
of local homeostasis in the face of systemic alterations.
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H.

Control of Local Circulation (see ref. 31, 125, 167, 172, 246, 268).

In

addition to negative feedback exerted on adrenergic nerve terminals and con¬
sequent modulation of adrenergic stimuli, the PGs have been found to modu¬
late or mediate the effects of the rnicrovasculature to a number of other
vasoactive substances including antagonism of angiotensin II induced vaso¬
constriction (90, 192)and mediation of bradykinin induced vasodilation (1,
94, 252).
mine (54).

They do not appear to be involved in the effects of exogenous dopa¬
Possible roles in relation to serotonin are undetermined.

PGs

are believed to be responsible for human reactive and functional hyperemia
(139).

Thus, the PGs, in addition to a direct vasodilatory function, also ap¬

pear to modulate control of the terminal bed by their interactions with other
vasoactive stimuli.

The general principle of PG synthesis in response to al¬

terations in local circulatory status is thus seen to hold at all levels of
the mammalian cardiovascular system.

I.

Hematologic Effects (see ref. 88, 96, 162, 174).

PGE-| and, more recently,

PGI^ have been recognized as potent agents in inhibiting platelet aggregation.
The mechanism is believed to be modulation of platelet cAMP (97, 251).

In

addition, TXA^ is known to be a substance formed by platelets capable of stimu¬
lation of platelet aggregation.
cal settings (51, 102, 160, 248).
of platelet TXA

2

J.

These findings have been documented in clini¬
At present, it is believed that the balance

and endothelial PG^ controls in vivo platelet activity.

Cyclic Nucleotides and Prostaglandins (see ref. 88, 136, 144, 231, 236,

257).

Elevation of intracellular cAMP following PGE , PGE-j , and PG^ has
2

been noted in many other tissues besides platelets.
as a unifying hypothesis to explain PG effects.

This has been invoked

This "middleman hypothesis"
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(88), which postulates PGs as intermediates for cAMP production is support¬
ed by the observed prolongatin of PGE vascular effects by phophodiesterase
inhibition (56).
It, therefore, seems unquestionable that PGs interact with cyclic nuclotides.

Yet many related questions remain unanswered:

how PG synthesis is initiated;
mains a mystery;

2.) the role of Ca

1.) it is unclear

in relation to PGs re¬

3.) whether PGs subserve a circulatory role is also there¬

by brought into controversy.

As to the question of stimulus for PG synthesis,

it is clear that virtually all noxious stimuli evoke PG biosynthesis.

Some

of these stimuli such as mechanical injury (161) might involve direct physi¬
cal destruction of membranes, thereby freeing arachadonic acid for PG bio¬
synthesis.

Other stimuli, such as hypoxia, compromised perfusion, nucleo-

tides (194), adenosine (7), Ca

2+

(278), or other electrolyte alterations may

activate phospholipase and PG synthetase as their mechanism of actions.

These

three stimuli of PG synthesis have in common the function of PGs as messengers
from cell membrane to cytoplasm.
The interaction of PGs and cyclic nucleotides is complicated by the
unclear role of cytoplasmic calcium.

Indeed, PGs, cAMP, and Ca

be involved in an intracellular mdnage h trois.
by Ca

2+

2+

seem to

PG synthesis is increased

stimulation of phospholipase but PGs are capable of inducing calcium

release from intracellular mitochondria (36).

PG synthesis appears to be

dependent on the oxidation-reduction capability of the cell
therefore, indirectly on nucleotides and cyclic nucleotides.

(193), and,
At

present,

..
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it is possible only to state that PGs may serve as intracellular hormones,
(291), without certain understanding of their roles and mechanisms.
The acceptance of PGs as intracellular hormones leads to the question
of their circulatory role.

Yet their measurable release in response to

extracellular insults and the extensive capacity of vascular endothelium to
metabolize PGs argues for a circulatory role.
have been demonstrated (143).

Furthermore, PG receptors

It seems likely, therefore, that PGs serve as

the messenger of the cell membrane both to the cytoplasm and to other local
cell populations.

The pulmonary bed serves to assure this localization, at

least of the primary PGs.

K.

Measurement of Prostaglandins.

has been measurement of PGs (191).

One of the major problems in PG research
Initially, investigators used a super¬

fusion bioassay to measure PGs, usually combined with chromatography.

This

method, however, presents significant problems in specificity (34, 44).
Other methods involving enzymatic and receptor assays have been abandoned
for lack of both sensitivity and specificity (3, 143).
Radioimmunoassay (RIA) has also been used (125) since the development
of specific antisera, although problems with this technique have been per¬
sistent (98, 208).

Specifically, measurements of PGs have generally result¬

ed in plasma levels in the nanomolar range, which differs by two to three or¬
ders of magnitude from other more recent and reliable measurements (84).
cause of erroneous plasma PG measurement is not clear.

The

The possibility of

lack of antiserum specificity and of non-specific binding of antibodies by
non-PG plasma elements have been proposed (98).
life of these compounds is very short.

Moreover, the plasma half-

This observation in conjunction with
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the realization that PGs are primarily local hormones, implies that measure¬
ment of levels of circulating PGs might not indicate either the rate of local
synthesis of PGs or the physiologic effects due to PGs.
tion of circulatory PG levels may be meaningless.

Thus, the determina¬

RIA does, nonetheless, hold

promise for future use.
The current gold standard for measurement of PGs is the combined use of
gas chromatography-mass spectrometry (84).

The major drawbacks of this method

are cost and time required.
The several techniques used require caution in acceptance of results of
PG measurement in plasma.

At present, the combination of PG synthesis block¬

ade is generally required in conduction with plasma measurement.

L.

Pharmacologic Manipulations of the Prostaglandins (see ref. 74).

Research

on PGs received a great boost with the demonstration in 1971 that aspirin and
several other non-steroidal anti-inflammatory drugs inhibit PG synthesis (78).
Subsequently, these compounds have been of great value in delineating PG ef¬
fects.

The drug concentrations required for inhibition have been more dif¬

ficult to establish,however.

The IC^q of indomethacin, the most commonly used

and most potent agent, has been assessed in vitro in guinea pig lungs to be
12 - 34 ng/ml

(69).

A recent in vivo study in rat kidneys showed a 69% re¬

duction in PGs as assessed by bioassay and an in vitro inhibition of 97%.(221).
Membrane stabilization and corollary inhibition of arachadonic acid re¬
lease has been reported to be the mechanism of action of corticosteroid in¬
hibition of PG synthesis (157).

Other membrane active agents, particularly

local anesthetics, can also inhibit in vitro PG synthesis (145), perhaps because of Ca

2+

effects.

'
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The existence of compounds which inhibit the action of PGs peripherally
has also been described (24).

These agents, because of competition for bind¬

ing sites, may also inhibit PG degradation enzymes, such as PGDH (44).
To date, however, few inhibitors of PG metabolism have come into wide
use, although diuretics have been reported to do so (250).

The rapid turn¬

over rate of PGDH renders the possibility of developing a complete inhibitor
uniikely.

■

84.

REFERENCES
1.

Abe, K., N. Irokawa, M. Yasujima, M. Seino, and S. Chiba:
kinin system and prostaglandins in the kidney.

The kallikrein-

Circ. Res. 43:254-260,

1978.
2.

AnggSrd, E., C. Larsson, and B. Samuelsson:

The distribution of 15-

hydroxy prostaglandin dehydrogenase and prostaglandin A13 reductase in
tissues of the swine.
3.

Prostaglandins:

en¬

Science 163:479-480, 1969.

Angg§rd, E. and E. Oliw:
the lung.

5.

81:396-404, 1971.

Anggard, E., F.M. Matschinsky, and B. Samuelsson:
zymatic assay.

4.

Acta Physiol. Scand.

Agents Actions

Formation and degradation of prostaglandins in
6:498-504, 1976.

Aitken, M.M. and J. Sanford:

Effects of prostaglandins in calves.

Brit.

J. Pharmac. 54:266P-267P, 1975.
6.

Alho, A., A. Jaattela, M. Lahdensuu, P. Rokkanen, and V. Avikanen:
Catecholamines in shock.

7.

Ally, A.I., D.F. Horrobin, R.A. Karmali, R.O. Morgan, M. Karmazyn, and M.
Manku:
muscle.

8.

Ann. Clin. Res. 9:157-163, 1977.

Adenosine as a natural prostaglandin antagonist in vascular smooth
Prostaglandins 14:109-117, 1977.

Altura, B.M.:

Glucocorticoid-induced protection in circulatory shock:

role of reticuloendothelial system function.

Proc. Soc. Exp. Biol. Med.

150:202-206, 1975.
9.

Altura, B.M. and B.T. Altura:

Vascular smooth muscle and prostaglandins.

Fed. Proc. 35:2360-2366, 1976.
10.

Andersen, N.H.:

Preparative thin layer and column chromatography.

J.

Lipid Res. 10:316-319, 1969.
11.

Andersen, N.H. and P.W. Ramwell:
Arch. Int. Med. 133:30-50, 1974.

Biological aspects of prostaglandins.

85.

12.

Anderson, F.L., W. Jubiz, A.C. Kralios, T.J. Tsagaris, and H. Kuida:
Plasma prostaglandin levels during endotoxin shock in dogs.
(Supp.

13.

II):

Circ. 45-46

11-124, 1972.

Anderson, F.L., W. Jubiz, T.J. Tsagaris, and FI. Kuida:

Prostaglandin F

levels during endotoxin-induced pulmonary hypertension in calves.
47-48 (Supp.
14.

IV):

IV-133, 1973.

Anderson, F.L., W. Jubiz, T.J. Tsagaris, and H. Kuida:
prostaglandin E and F release in dogs.

15.

Circ.

Endotoxin-induced

Am. J. Physiol. 228:410-414, 1975.

Anderson, F.L., W. Jubiz, T.J. Tsagaris, and FI. Kuida:

Prostaglandin E

and F levels during endotoxin-induced pulmonary hypertension in calves.
Am. J. Physiol. 228:1479-1482, 1975.
16.

Anderson, R.J., R.J. Berl, K.M. McDonald, and R.W. Schrier:
glandins:
excretion.

17.

effects on blood pressure, renal blood flow, sodium and water
Kidney Inter. 10:205-215, 1976.

Aukland, K., A. Kirkebo,and I. Tyssebotn:
in dehydration and shock.

18.

Prosta¬

Intrarenal blood flow in dogs

J. Physiol. 245:99P-1 OOP, 1975.

Bailie, M.D., J.A. Barbour, and J.B. Hook:

Effects of indomethacin on

furosemide-induced changes in renal blood flow.

Proc. Soc. Exp. Biol.

Med. 148:1173-1176, 1975.
19.

Bakhle, Y.S.:

The pharmacokinetic function of the lung.

1ism, A.F. Junod and R. deHaller, eds. New York:

Lung Metabo-

Academic Press, pp.

293-299, 1975.
20.

Baue, A.E.:

Recent developments in the study and treatment of shock.

Surgery, Gynec. Obstet. 127:849-878, 1968.
21.

Baue, A.E.:

Metabolic abnormalities of shock.

56:1059-1071 , 1 976.

Surg. Clin. North Amer.

86.

22.

Beilen, L.J. and J. Bhattacharya:

The effect of prostaglandin synthesis

inhibitors on renal blood flow distribution in conscious rabbits.

J.

Physiol. 269:395-405, 1977.
23.

Bell, R.D., R.J. Sinclair, and W.L. Parry:

The effects of indomethacin

on autoregulation and the renal response to hemorrhage.

Circ. Shock

2:57-63, 1975.
24.

Bennett, A. and J. Posner:

Studies on prostaglandin antagonists.

Br.

J. Pharmac. 42:584-594, 1971.
25.

Berry, H., J.G. Collier, and J.R. Vane:

The generation of kinins in

the circulation of the dog during hypotension from blood loss.
Biochemical, Pharmacological, and Clinical Aspects,
Bach,eds.. New York:
26.

Bito, L.Z.:

Shock:

A. Bertelli and N.

Plenum Press, pp. 153-157, 1970.

Saturable, energy-dependent, transmembrane transport of

prostaglandins against concentration gradients.

Nature 256:134-136,

1975.
27.

Bito, L.Z., R.A. Baroody, and M.E. Reitz:

Dependence of pulmonary prosta¬

glandin metabolism on carrier-mediated transport process.

Am. J. Physiol.

232 :E382-E387, 1977.
28.

Bito, L.Z., H. Davson, and E.V. Salvador:

Inhibition of in vitro con-

centrative prostaglandin accumulation by prostaglandins, prostaglandin
analogues, and by some inhibitors of organic anion transport.

J.

Physiol. 256:257-271, 1976.
29.

Blackwell, G.J., R.J. Flower, and J.R. Vane:

Rapid reduction of prosta¬

glandin 15-hydroxy dehydrogenase activity in rat tissues after treatment
with protein-synthesis inhibitors.
30.

Blasingham, C. and E.E. Selkurt:

Br. J. Pharmac. 55:233-238, 1975.
Changes in metabolism of prostaglandin

E by the dog lung during hemorrhagic shock.

Fed. Proc. 35:608, 1976.

87.

31.

Blumberg, A.L., S.E. Denny, G.R. Marshal 1, and P. Needleman:
sel-hormone interactions:

Blood ves¬

angiotensin, bradykinin, and prostaglandins.

Am. J. Physiol. 232:H3Q5-H310, 1977.
32.

Brody, M.J. and P.J. Kadowitz:
nomic nervous system.

33.

Prostaglandins as modulators of the auto¬

Fed. Proc. 33:48-60, 1974.

Bryant, L.R., J.K. Trinkle, and L. Dubilier:
physiology after hemorrhagic shock.

34.

Bult, H. and I.L. Bonta:

Surgery 68:512-519, 1970.

Prostaglandin endoperoxides, serotonin, and

the superfused rabbit aorta:

possible pitfalls in the bioassay of the

rabbit aorta contracting substance.
35.

Acute respiratory patho¬

Agents Actions 6:712-720, 1976.

Caldwell, B.V., S. Burstein, W.A. Brock, and L. Speroff:
assay of the F Prostaglandins.

36. Carafoli, E. and F. Crovetti:

Radioimmuno¬

J. Clin. Endocr. Metab, 33:171-175, 1971.
Interactions between prostaglandin E-j and

calcium at the level of the mitochondrial membrane.

Arch. Biochem.

Biophys. 154:40-46, 1973.
37.

Cavanaugh, D., P.J. Clark, and A.G. McLeod:
type.

38.

Am. J. Obstet.

Gynec. 102:13-20, 1968.

Champion, H.R., R.T. Jones, B.F. Trump, R. Decker, S. Wilson, M. Miginski,
and W. Gill:
shock.

39.

Septic shock of endotoxin

A clinicopathologic study of hepatic dysfunction following

Surgery, Gynec. Obstet. 142:657-663, 1976.

Chaudry, I.H. and A.E. Baue:

Depletion and replenishment of cellular

cyclic adenosine monophosphate in hemorrhagic shock.

Surgery, Gynec.

Obstet. 145:877-881, 1977.
40.

Chaudry, I.H., M.M. Sayeed, and A.E. Baue:

The effect of low ATP on

glucose uptake in soleus muscle during hemorrhagic shock.
Exp. Biol. Med. 144:321-325, 1973.

Proc. Soc.

'

.

■

88.

41.

Chaudry, I.H., K.A. Wichterman, and A.E. Baue:
tissue adenine nucleotide levels.

42.

Christy, J.H.:

Effect of sepsis on

Surgery 85:205-211, 1979.

Pathophysiology of gram-negative shock.

Am. Heart J.

81 :694-701 , 1971.
43.

Collier, J.G., A.G. Herman, and J.R. Vane:

Appearance of prostaglandins

in the renal venous blood of dogs in response to acute systemic hypo¬
tension produced by bleeding or endotoxin.

J. Physiol. 230:19P-20P,

1973.
44.

Crutchley, D.J. and P.J. Piper:
tion of prostaglandins

Inhibition of the pulmonary inactiva¬

in vivo by di-4-phloretin phosphate.

Br. J.

Pharmac. 54:301-307, 1975.
45.

Crutchley, D.J. and P.J. Piper:

Comparative bioassay of prostaglandin E^

and its three pulmonary metabolites.
46.

Br. J. Pharmac. 54:397-399, 1975.

Culp, J.R., E.G. Erdos, L.B. Hinshaw, and D.D. Holmes:

Effects of

anti-inflammatory drugs in shock caused by injection of living E. coli
cells.
47.

Proc. Soc. Exp. Biol. Med. 137:219-223, 1971.

Data, J.L., L.C.T. Chang, and A.S. Nies:

Alteration of canine renal

vascular response to hemorrhage by inhibitors of prostaglandin synthesis.
Am. J. Physiol. 230:940-945, 1976.
48.

Dawson, C.A., B.0. Cozzini, and A.J. Lonigro:

Metabolism of (2-^C)

prostaglandin E-j on passage through the pulmonary circulation.

Can. J.

Physiol. Pharmac. 53:610-615, 1975.
49.

Demling, R.H., S.L. Selinger, R.D. Bland, and N.C. Staub:

Effect of

acute hemorrhagic shock on pulmonary microvascular fluid filtration and
protein permeability in sheep.

Surgery 77:512-519, 1975.

89.

50.

Derks, C.M. and R.M. Peters:

The effect of shock and fat embolus on

pulmonary mechanics and gas exchange.

Surgery, Gynec. Obstet. 138:413-

416, 1974.
51.

Dougherty, J.H., Jr., D.E. Levy, and B.B. Weksler:
in acute cerebral ischemia.

52.

Platelet activation

Lancet 1:821-824, 1977.

Dousa, T.P. and R.R. Dozois:

Interrelationships between histamine,

prostaglandins, and cyclic AMP in gastric secretion:

a hypothesis.

Gastroenterology 73:904-912, 1977.
53.

Dray, F., B. Charbonnel, and J. Maclouf:

Radioimmunoassay of prosta¬

glandins Fa, E-| , and E^ in human plasma.

Europ. J. Clin. Invest. 5:311-

318, 1975.
54.

Dressier, W.E., G.V. Rossi, and R.F. Orzechowski:

Evidence that renal

vasodilation by dopamine does not involve release of prostaglandin. J.
Pharm. Pharmac. 27:203-204, 1975.
55.

Duff, J.H.:

Cardiovascular and metabolic changes in shock and sepsis.

Eur.’Surg. Res. 9:155-165, 1977.
56.

Dunham, E. and B.G. Zimmerman:
induced vasodilatation.

57.

Dunn, M.J. and V.L. Flood:

Effect of theophylline on prostaglandin

Pharmacologist 13:292, 1971.
Prostaglandins and the kidney.

Am. J.

Physiol. 233:FI69-FI84, 1977.
58.

Egdahl, R.H., M.M. Meguid, and F. Aun:

The importance of the endocrine

and metabolic responses to shock and trauma.

Crit. Care Med. 5:257-263,

1977.
59.

Egerton-Vernon, J.M. and J.R. Bedwani:

Prostaglandin 15-hydroxy dehydro¬

genase activity during pregnancy in rabbits and rats.
33:405-408, 1975.

Eur. J. Pharmac.

■

rfj

90.

60.

Elin, R.J. and S.M. Wolff:

Biology of Endotoxin.

Ann. Rev. Med. 27:

127-141 , 1976.
61.

Eling, T.E. and M.W. Anderson:

Studies on the biosynthesis, metabolism,

and transport of prostaglandins by the lung.

Agents Actions 6:543-546,

1976.
62.

Ellis, E.F., A.S. Nies, and J.A. Oates:
contraction by thromboxane A^.

63.

Stroke 8:480-483, 1977.

Erdos, E.G., L.B. Hinshaw, and C.C. Gill:
endotoxin shock in the dog.

Cerebral arterial smooth muscle

Effect of indomethacin in

Proc. Soc. Exp. Biol. Med. 125:916-919,

1967.
64.

Essiet, G.S. and W.M. Stahl:

Water and electrolyte content of tissues

in hemorrhagic shock and surgical trauma.

Surgery, Gynec. Obstet. 137:

11-14, 1973.
65.

Fanburg, B.L.:

Prostaglandins and the lung.

Am. Rev. Resp. Pis. 108:

482-489, 1973.
66.

Feldberg, W. and P.N. Saxera:
in body temperature in rats.

67.

Ferreira, S.H. and J.R. Vane:

Prostaglandins, endotoxin, and Lipid A
J, Physiol. 249:601-615, 1975.
Prostaglandins:

and release into the circulation.
68.

their disappearance from

Nature 216:868-873, 1967.

Fitzpatrick, T.M., M. Johnson, P.A. Kot, P.W. Ramwell, and J.C. Rose:
Vasoconstrictor response to arachadonic acid in the isolated hind limb
of the dog.

69.

Fjalland, B.:

Br. J. Pharmac. 59:269-273, 1977.
Inhibition by non-steroidal anti-inflammatory agents of

the release of rabbit aorta contracting substance and prostaglandins
from guinea-pig lungs.

J. Pharm. Pharmac. 26:448-451, 1974.

91.

70.

Flamenbaum, W. and J.C. Kleinman:
or "a trip down the rabbit hole."
Ramwell, ed.. New York:

71.

Fleck, A.:

Prostaglandins and renal function,
The Prostaglandins, Vol. 3, P.W.

Plenum Press, pp. 267-328, 1977.

The early metabolic response to injury.

and Experimental Aspects,

Shock:

I.McA. Ledingham, ed., Amsterdam:

Clinical
Excerpta

Medica, pp. 57-77, 1976.
72.

Fletcher, J.R., C.M. Flerman, and P.W. Ramwell:

Improved survival in

endotoxemia with aspirin and indomethacin pretreatment.

Surg. Forum 27:

11-12, 1976.
73.

Fletcher, J.R. and P.W. Ramwell:

Modification, by aspirin and indometha¬

cin, of the hemodynamic effects of E. coli endotoxin in the dog.

Br. J.

Pharmac. 61 :1 75-181 , 1977.
74.

Fletcher, J.R. and P.W. Ramwell:

Altered lung metabolism of prosta¬

glandins during hemorrhagic and endotoxin shock.

Surg. Forum 28:184-186,

1977.
75.

Fletcher, J.R. and P.W. Ramwell:

Lidocaine or indomethacin improves

survival in baboon endotoxin shock.
76.

J. Surg. Res. 24:154-160, 1978.

Fletcher, J.R., P.W. Ramwell, and C.M. Flerman:
hemodynamic course of endotoxin shock.

77.

Flower, R.T.:

Prostaglandins and the

J. Surg. Res. 20:589-594, 1976.

Drugs which inhibit prostaglandin synthesis.

Pharmac.

Rev. 26:33-67, 1974.
78.

Flower, R., R. Gryglewski, K. Herbaczynska-Cedro, and J.R. Vane:
fects of anti-inflammatory drugs on prostaglandin biosynthesis.

Ef¬
Nature

238:104-106, 1972.
79.

Flynn, J.T.:

Endotoxin shock in the rabbit:

glandin and arachadonic acid administration.
555-566, 1978.

the effects of prosta¬
J. Pharmac. Exp. Ther. 206:

92.

80.

Flynn, J.T., H.E. Appert, and J.M. Howard:
E-j, and

Arterial prostaglandin A-j ,

concentrations during hemorrhagic shock in the dog.

Circ.

Shock 2:155-163, 1975.
81.

Flynn, J.T. and A.M. Lefer:
shock.

82.

Prostaglandin metabolism during circulatory

Biochim. Biophys. Acta 497:775-784, 1977.

Flynn, J.T. and A.M. Lefer:

Beneficial effects of arachadonic acid

during hemorrhagic shock in the dog.
83.

Circ. Res. 40:422-428, 1977.

Fonkalsrud, E.W., H. Higashijima, A.K. Sarwat, E. Arima, and M. Sanchez:
Evaluation of pulmonary function in the ischemic, non-venti1ated canine
lung.

84.

Surgery 76 :527-532, 1974.

Frolich, J.C.:

Gas chromatography-mass spectrometry of prostaglandins.

The Prostaglandins, Vol. 3, P.W. Ramwell, ed.. New York:

Plenum Press,

pp. 1-39, 1977.
85.

86.

Fronek, A. and T. Witzel:

Hemodynamics of the terminal vascular bed in

canine hemorrhagic shock.

Surgery 75:408-415, 1974.

Fumagalli, R., G.C. Folco, and D. Longiane:
on central functions.

Prostaglandins and Thromboxanes, F. Berti, B.

Samuelsson, and G.P. Velo, eds.,
87.

Influence of prostaglandins

Gerkens, J.F. and D.G. Shand:

New York:

Plenum Press, pp. 383-401, 1977.

Inhibition by indomethacin of hepatic

arterial autoregulation during hemorrhage in the dog.

Pharmacologist

17:221 , 1975.
88.

Gerrard, J.M. and J.G. White:

Prostaglandins and thromboxanes:

men" modulating platelet function in hemostasis and thrombosis.

"middle¬
Prog.

Hemostasis Thrombosis 4:87-125, 1978.
89.

Gillis, C.N. and J.A. Roth:
active hormones.

Pulmonary disposition of circulating vaso¬

Biochem. Pharmac. 25:2547-2553, 1976.

93.

90.

Gimbrone, M.A., Jr. and R.W. Alexander:

Angiotensin II stimulation of

prostaglandin production in cultured human vascular endothelium.
Science 189:219-220, 1975.
91.

Glenn, T.M.:

Alteration of the course of feline post-oligemic shock by

prostaglandin infusion.
92.

Glenn, T.M. and A.M. Lefer:
splanchnic ischemia.

93.

Fed. Proc. 31 :545 , 1 972.
Role of lysosomes in the pathogenesis of

Circ. Res. 27:783-797, 1970.

Glenn, T.M., G.T. Raflo, and S.C. Wangensteen:
prostaglandin E-j and

in endotoxin shock.

Beneficial effect of
Pharmacologist 13:293,

1971.
94.

Goldberg, M.R., B.M. Chapnick, P.D. Joiner, A.L. Hyman, and P.J.
Kadowitz:

Influence of inhibitors of prostaglandin synthesis on veno-

constrictor responses to bradykinin.

J. Pharmac. Exp. Ther. 198:357-

365, 1976.
95.

Golub, M., P. Zia, M. Matsuno, and R. Horton:
glandins A-j and E-j in man.

96.

Gorman, R.:

Fed. Proc. 38:83-88, 1979.

Gorman, R.R., S. Bunting, and O.V. Miller:
adenylate cyclase by prostacyclin.

98.

Invest. 56:1404-1410, 1975.

Modulation of human platelet function by prostacyclin and

thromboxane
97.

J. Clin.

Metabolism of prosta¬

Granstrom, E.:

Modulation of human platelet

Prostaglandins 13:377-388, 1977.

Radioimmunoassay of prostaglandins.

Prostaglandins 15:

3-17, 1978.
99.

Grden, K. and B. Samuelsson:

Prostaglandins and related factors.

Thin layer chromatography of prostaglandins.
1964.

XIX.

J. Lipid. Res. 5:116-120,

94.

100.

Greenway, C.V. and V.S. Murphy:

Mesenteric vasoconstriction after endo¬

toxin administration in cats pretreated with aspirin.

Br. J. Pharmac.

43:259-269, 1971.
101.

Gross, D.M., V.M. Mujovic, W. Jubiz, and J.W. Fisher:

Enhanced erythro¬

poietin and prostaglandin E production in the dog following renal artery
constriction.
102.

Proc. Soc. Exp. Biol. Med. 151:498-501, 1976.

Gryglewski, R.J., A. Szczeklik, and R. Nizankowski:

Antiplatelet ac¬

tion of intravenous infusion of prostacyclin in man.

Thromb. Res. 13:

153-163, 1978.
103.

Haglund, U., H. Myrvold, and D. Lundgren:
tion in regional intestinal shock.

104.

Hall, R.C., R.L. Hodge, R.

Cardiac and pulmonary func¬

Arch. Surg. 113:963-969, 1978.

Irvine, F. Katie, and J.M. Middleton:

effect of aspirin on the response to endotoxin.

The

Aust. J. Exp. Biol.

Med. Sci. 50:589-601, 1972.
105.

Hall, W.J., P. O'Neill, and J.D. Sheehan:

The role of prostaglandins

in cholinergic neurotransmission in the guinea pig.

Eur. J. Pharmac.

34:39-47, 1975.
106.

Hammond, G.L., L.H. Cronau, D. Whittaker, and C.N. Gillis:
prostaglandin E-j and A-j in the human pulmonary circulation.

Fate of
Surgery

81 :716-722, 1977.
107.

Harris, P.D., D.E. Longnecker, E.K. Greenwald, and F.N. Miller:

Small

vessel constriction in the rat cremaster during the early phase of
moderate hemorrhagic hypotension.
Der septische schock.

Microvasc. Res. 10:29-37, 1975.

108.

Haschek, H.:

Med. Klin. 71:2203-2209, 1976.

109.

Hedqvist, P.:

Basic mechanisms of prostaglandin action on autonomic

transmission.

Ann. Rev. Pharm. Tox. 17:259-279, 1977.

'

.

95.

110.

Henrich, W.L., R.J. Anderson, A.S. Berns, K.M. McDonald, P.J. Paulsen,
T. Berl, and R.W. Schrier:

The role of renal nerves and prostaglandins

in control of renal hemodynamics and plasma renin activity during hemor
rhagic hypotension in the dog.
111.

J. Clin. Invest. 61:744-750, 1978.

Henrich, W.L., T. Berl, K.M. McDonald, R.J. Anderson, and R.W. Schrier:
Angiotensin II, renal nerves, and prostaglandins in renal hemodynamics
during hemorrhage.

112.

Am. J. Physiol. 235:F46-F51, 1978.

Herbaczynska-Cedro, K. and J.R. Vane:

Contribution of intrarenal

generation of prostaglandin to autoregulation of renal blood flow in
the dog.
113.

Circ. Res. 33:428-436, 1973.

Herman, A.G. and J.R. Vane:

Release of renal prostaglandin during endo

toxin-induced hypotension.
114.

Eur. J. Pharmac. 39:79-90, 1976.

Higgins, C.B. and E. Braunwald:

The prostaglandins:

physiologic, and clinical considerations.
115.

Hilton, J.G. and C.H. Wells:

biochemical,

Am. J. Med. 53:92-112, 1972.

Effects of indomethacin and nicotinic

acid on E. coli endotoxin shock in anesthetized dogs.

J. Trauma 16:

968-973, 1976.
116.

Hinshaw, L.B., L.A. Solomon, E.G. Erdos, D.A. Reins, and B.J. Gunter:
Effects of acetyl salicylic acid on the canine response to endotoxin.
J. Pharmac. Exp. Ther. 157:665-671, 1967.

117.

Hissen, W., J.S. Fleming, M.E. Bierwager, and M.H. Pindell:

Effect of

prostaglandin E-j on platelet aggregation in vitro and in hemorrhagic
shock.
118.

Microvasc. Res. 1:374-378, 1969.

Hook, R. and C.N. Gillis:
E-j by rabbit lung.

119.

The removal and metabolism of prostaglandin

Prostaolandins 9:193-201 , 1975.

Horrobin, D.F.: Prostaglandins:
Significance.

Montreal:

Physiology, Pharmacology, and Clinical

Eden Press, 1978.

96.

120.

Horton, E.W.:

The prostaglandins.

Proc. R. Soc. B 182:411-426, 1972.

121.

Hutchins, P.M., J. Goldstone, and R. Wells:

Effects of hemorrhagic

shock on the microvasculature of skeletal muscle.

Microvasc. Res. 5:

131-140, 1973.
122.

Hyman, A.L., E.W. Spannhake, and P.J. Kadowitz:
lung.

123.

Prostaglandins and the

Am. Rev. Resp. Pis. 117:111-136, 1978.

Imamura, M. and G.H.A. Clowes, Jr.:

Hepatic blood flow and oxygen con¬

sumption in starvation, sepsis, and septic shock.

Surgery, Gynec.

Obstet. 141 :2 7-34, 1975.
124.

Isakson, P.G., F. Shofer, R.C. McKnight, R.A. Feldhaus, A. Raz, and P.
Needleman:
endotoxemia.

125.

J. Pharmac. Exp. Ther. 200:614-622, 1977.

Itskovits, H.D. and J.C. McGiff:
circulation.

126.

Prostaglandins and the renin-angiotensin system in canine

Hormonal regulation of the renal

Circ. Res. 34-35 (Supp.

Jaffe, B.M. and H.R. Behrman:

I):

1-65 - 1-73, 1974.

Prostaglandins E, A, and F. Methods

in Hormone Radioimmunoassay, B.M. Jaffe and H.R. Behrman, eds.. New York
Academic Press, pp. 19-34, 1974.
127.

Jaffe, B.M., C.W. Parker, G.R. Marshall, and P. Needleman:

Renal con¬

centrations of prostaglandin E in acute and chronic renal ischemia.
Biochem. Biophys. Res. Commun. 49:799-805, 1972.
128.

Jakschik, B.A., J.L. Kourik, and P. Needleman:
and release by the lung during hemorrhage.

129.

Prostaglandin metabolism

Pharmacologist 16:197, 1974.

Jakschik, B.A., G.R. Marshall, J.L. Kourik, and P. Needleman:

Profile

of circulating vasoactive substances in hemorrhagic shock and their
pharmacologic manipulation.

J. Clin.

Invest. 54:842-852, 1974.

97.

130.

January, C.T. and B.A. Schottelius:

Electrophysiologic and inotropic

actions of prostaglandin F^a in rat myocardium.

Proc. Soc. Exp. Biol.

Med. 147:403-406, 1974.
131.

Johnson, F.W. and D.M. Nicoloff:
during shock.

132.

Fed. Proc. 32:357, 1973.

Johnston, P.A. and E.E. Selkurt:
lease of prostaglandin E.

133.

Pulmonary capillary hemodynamics

Effect of hemorrhagic shock on re¬

Am. J. Physiol. 230:831-838, 1976.

Kadar, D. and F.A. Sunahara:

Inhibition of prostaglandin effects by

ouabain in the canine vascular tissue.

Can. J. Physiol. Pharmac. 47:

871-879, 1969.
134.

Kadowitz, P.J., P.D. Joiner, A.L. Hyman, and W.J. George:

Influence

of prostaglandins E-j and F^ on pulmonary vascular resistance, isolated
lobar vessels, and cyclic nucleotide levels.

J. Pharmac. Exp. Ther.

192:677-687, 1975.
135.

Katz, R.L. and G.J. Katz:
derations.

136.

basic and clinical consi¬

Anesthesiology 40:471-493, 1974.

Kelliher, G.J. and T.M. Glenn:
induced arrhythmia.

137.

Prostaglandins:

Effect of prostagl andin E-j on ouabain-

Eur. J. Pharmac. 24:410-414, 1973.

Kenimer, J.G., V. Goldberg, and M. Blecker:

The endocrine systems:

The Prostaglandins, Vol. 3, P.W. Ramwell, ed.. New York:

Plenum Press,

pp. 77-108, 1977.
138.

Kessler, E., R.C. Hughes,E.N. Bennett, and S.M. Nadola:

Evidence for

the presence of prostaglandin-like material in the plasma of dogs with
endotoxin shock.
139.

Kilbom, ft

J. Lab. Clin. Med. 81:85-94, 1973.

and ft. Wennhalm:

lators of blood flow in man:
functional hyperaemia.

Endogenous prostaglandins as local regu¬
effect of indomethacin on reactive and

J. Physiol. 257:109-121, 1976.

98.

140.

Kim, S.I. and W.C. Shoemaker:

Role of acidosis in the development of

increased pulmonary vascular resistance and shock lung in experimental
hemorrhagic shock.
141.

Koss, M.C. and J. Nakano:
F0

in cats.

Cardiac arrhythmias induced by prostaglandin

Prostaglandins 8:179-185, 1974.
-

col

142.

Surgery 73:723-729, 1973.

Krebs, R. and K. Schror:

Actions of prostaglandin

on myocardial

mechanics, coronary vascular resistance, and oxygen consumption in the
guinea-pig isolated heart preparation.

Br. J. Pharmac. 55:403-408,

1 975.
143.

Kuehl, F.A., Jr. and J.L. Humes:

Direct evidence for a prostaglandin

receptor and its application to prostaglandin measurements.

Proc.

Natn. Acad, Sci. U.S.A. 69:480-484, 1972.
144.

Kuehl, F.A., J.C. Humes, V.J. Cirillo, and E.A. Ham:
prostaglandins in hormone action.

Cyclic AMP and

Adv. Cyclic Nucleotide Res. 1 :493-

502, 1972.
145.

Kunze, H., E. Bohn, and W. Vogt:

Effects of local anesthetics on

prostaglandin biosynthesis in vitro.

Biochem. Biophys. Acta 360:

260-269, 1974.
146.

Landesman, S.H. and S.L. Gorbach:

Gram negative sepsis and shock.

Ortho. Clin. North Amer. 9:611-625, 1978.
147.

Ledingham, I. McA. and J.R. Parratt:
Shock:

148.

Pathophysiology of shock.

Clinical and Experimental Aspects.

I.McA. Ledingham, ed.,

Amsterdam:

Excerpta Medics, pp. 1-20, 1976.

Lee, J.B.:

Cardiovascular-renal effects of prostaglandins.

Arch.

Int.

Med. 133:56-76, 1974.
149.

Lefer, A.M.:

Role of a myocardial depressant factor in the pathogenesis

of circulatory shock.

Fed. Proc. 29:1836-1844, 1970.

99.

150.

Leffler, C.W. and J.C. Passmore:

Effects of indomethacin on hemo¬

dynamics of dogs in refractory hemorrhagic shock.

J. Surg. Res. 23:

392-399, 1977.
151.

Lewis, G.P. and P.J. Piper:

Inhibition of release of prostaglandins

as an explanation of some of the actions of anti-inflammatory cortico¬
steroids.
152.

Nature 254:308-311, 1975.

Limas, C.J. and J.N. Cohn:

Stimulation of vascular smooth muscle

Na-K ATPase by vasodilators.
153.

Circ. Res. 35:601-607, 1974.

MacDonald, J.A.E., G.F. Milligan, A. Mellon, and I. McA. Ledingham:
Ventricular function in experimental hemorrhagic shock.

Surgery,

Gynec. Obstet. 140:572-581, 1975.
154.

Machiedo, G.W., C.S. Brown, J.E. Lavigne, and B.F. Rush, Jr.:
glandin E-j as a therapeutic agent in hemorrhagic shock.

Prosta¬

Surg. Forum

24:12-14, 1973.
155.

Machiedo, G.W., C.S. Brown, J.E. Lavigne, and B.F. Rush, Jr.:

Beneficial

effect of prostaglandin E-j in experimental hemorrhagic shock.

Surgery,

Gynec. Obstet. 143:433-436, 1976.
156.

Maclouf, J., H. Sors, and M. Rigaud:
biosynthesis:

157.

a review.

Recent aspects of prostaglandin

Biomedicine 26:362-375, 1977.

Madan, B.R., R.S. Gupta, and V. Madan:

Actions of prostaglandins E-|,

^2’ ^la’ anc* ^2a’ in ouabain-induced arrhythmia and maximal electroshock
seizures.
158.

Indian J. Med. Res. 62:1647-1651, 1974.

Magilligan, D.J. and S.I. Schwartz:
systemic shock.

159.

Malik, K.U.:

Platelet response to regional and

Surgery 77:268-274, 1975.

Prostaglandins - modulation of adrenergic nervous system.

Fed. Proc. 37:203-207, 1978.

'

100.

160.

Malmsten, C., M. Hamberg, J. Svensson, and B. Samuelsson:
endoperoxides.
lets:

8.

Prostaglandin

Physiologic role of an endoperoxide in human plate¬

hemostatic defect due to platelet cyclo-oxygenase deficiency.

Proc. Natn. Acad. Sci. U.S.A. 72:1446-1450, 1975.
161.

Markelonis, G. and J. Garbus:

Alterations of intracellular oxidative

metabolism as stimuli evoking prostaglandin biosynthesis.

Prosta-

glandins 10:1087-1105, 1975.
162.

Marx, J.L.:

Blood clotting:

the role of prostaglandins.

Science 196:

1072-1075, 1977.
163.

Mathe, A.A.:

Prostaglandins and the lung.

P.W. Ramwell, ed. New York:
164.

The Prostaglandins, Vol. 3,

Plenum Press, pp. 169-223, 1977.

Math6, A.A., P. Hedqvist, K. Strandberg, and C.A. Leslie:
prostaglandin function in the lung.

Aspects of

New Engl. J. Med. 296:850-855 and

910-915, 1977.
165.

McCurdy, J.R., L.J. Greenfield, A.V. Prancan, and J. Nakano:

Cardio¬

vascular, hematologic, and metabolic effects of prostaglandin E-j in
endotoxin shock.
166.

168.

11-186, 1972.

McGiff, J. C., K. Crowshaw, and H.D. Itskovits:
nal function.

167.

Circ. 45-46 (Supp. II):

Prostaglandins and re¬

Fed. Proc. 33:39-47, 1974.

McGiff, J.C., K.U. Malik, and N.A. Terragno:

Prostaglandins as deter¬

minants of vascular reactivity.

Fed. Proc. 35:2382-2387, 1976.

McGiff, J.C., and P. Y-H. Wong:

Compartmentalization of prostaglandins

and prostacyclin

within the kidney:

implications for renal function.

Fed. Proc. 38:89-93, 1979.
169.

McGovern, V.J.:

The pathophysiology of gram negative septicemia.

Pathology 4:265-271 , 1972.

.

101

170.

McHenry, M.C. and W.A. Hawk:
bacilli.

171.

Med. Clin. North Amer. 58:623-638, 1974.

Messina, E.J., R. Weiner, and G. Kaley:
prostaglandins E-j, E£, and
cle.

172.

Microcirculatory effects of

in the rat mesentery and cremaster mus¬

Microvasc. Res. 8:77-87, 1974.

Messina, E.J., R. Weiner, and G. Kaley:
culatory control.

173.

Bacteremia caused by gram-negative

Prostaglandins and local cir¬

Fed. Proc. 35:2367-2375, 1976.

Micossi, P., A.E. Pontiroli, S.H. Baron, R.C. Tamayo, F. Lengyel ,
M. Berilogud, U. Raggi, G. Narbiato, and P.P. Foa:

Aspirin stimulates

insulin and glucagon secretion and increases glucose tolerance in nor¬

174.

mal and diabetic subjects.

Diabetes 27:1196-1204, 1978.

Moncada, S. and J.R. Vane:

The role of prostacyclin in vascular tissue.

Fed. Proc. 38:66-71, 1979.
175.

Morrison, D.C. and R.T. Ulevitch:
on host mediation systems.

176.

The effects of bacterial endotoxins

Am. J. Path. 93:575-617, 1978.

Moss, G.S., B. Newson, and T.K. Das Gupta:

The normal electron histo¬

chemistry and the effect of hemorrhagic shock on the pulmonary sur¬
factant system.
177.

Surgery, Gynec. Obstet. 140:53-58, 1975.

Myerowitz, R.L., A.A. Medeiros, and T.F. O'Brien:
with baciHernia due to gram-negative organisms.

Recent experience
J. Inf. Pis. 124:239-

246, 1971.
178.

Nagakawa, B., L. Goldberg, J. McCartney, and T. Matsumoto:

The effect

of dopamine in renal microcirculation in hemorrhagic shock in dogs.
Surgery, Gynec. Obstet. 142:871-874, 1976.
179.

Nagler, A.L. and R. McConn:
Shock:
sterdam:

The role of humoral factors in shock.

Clinical and Experimental Aspects.
Excerpta Medica, pp. 79-109, 1976.

I.McA. Ledingham, ed., Am¬

.

f

.

102

180.

Nakano, J. :

Metabolism of prostaglandin E-j in dog kidneys.

Br. J.

Pharmac. 40:317-325, 1970.
181.

Nakano, J. :

Metabolism of prostaglandin E-j in kidney and lung.

Fed.

Proc. 29:746, 1970.
182.

Nakano, J.:

Prostaglandins and the ciruculation.

Mod. Concepts

Cardiovasc. Pis. 40:49-54, 1971.
183.

Nakano, J. :
tice.

184.

The prostaglandins:

their significance in clinical prac¬

Med. Times 102:47-58, 1974.

Nakano, J. and M.C. Koss:

Pathophysiologic roles of prostaglandins

and the action of aspirin-like drugs.

Southern Med. J. 66: 709-723,

1 973.
185.

Nakano, J. and J.R. McCurdy:
E-j.

186.

Cardiovascular effects of prostaglandin

J. Pharmac. Exp. Ther. 1 56:538-547, 1967.

Nakano, J., B. Montague, and B. Darrow:

Metabolism of prostaglandin

E-j in human plasma, uterus, and placenta, in swine ovary, and in the
rat testicle.
187.

Biochem. Pharmac. 20:2512-2514, 1971.

Nakano, J. and A.V. Prancan:

Metabolic degradation of prostaglandin

E-j in the rat plasma and in rat brain, heart, lung, kidney, and testicle
homogenates.
188.

J. Pharm. Pharmac. 23:231-232, 1971.

Nakano, J. and A.V. Prancan:

Metabolic degradation of prostaglandin

E-j in the lung and kidney of rats in endotoxin shock.

Proc. Soc. Exp.

Biol. Med. 144:506-508, 1973.
189.

Nishijima, H., M.H. Weil, H. Shubin, and J. Cavanilles:

Hemodynamic

and metabolic studies on shock associated with gram negative bacteremia.
Medicine 52:287-294, 1973.

103.

190.

Needleman, P.:
heart.

191.

The synthesis and function of prostaglandins in the

Fed, Proc. 35:2376-2381, 1976.

Needleman, P.:

Experimental criteria for evaluating prostaglandin

biosynthesis and intrinsic function.

Biochem. Pharmac. 27:1515-1518,

1978.
192.

Needleman, P., J.R. Douglas, Jr., B. Jakschik, P.B. Stoecklein, and
E.M. Johnson, Jr.:

Release of renal prostaglandin by catecholamine:

relationship to renal endocrine function.

J. Pharmac. Exp. Ther. 188:

453-460, 1974.
193.

Needleman, P., B. Jakschik, and E.M. Johnson, Jr.:
ment for relaxation of vascular smooth muscle.

Sulfhydryl require¬
J. Pharmac. Exp. Ther.

187:324-331, 1973.
194.

Needleman, P., M.S. Minkes, and J.R. Douglas, Jr.:

Stimulation of

prostaglandin biosynthesis by adenine nucleotides.

Circ. Res. 34:455-

460, 1974.
195.

Needleman, P. and K.C. Nicolaou:

Cardiac and renal prostaglandin I^.

J. Clin. Invest. 61:839-849, 1978.
196.

Niinikoski, J.:

Tissue oxygenation in hypovolemic shock.

Ann. Clin.

Res. 9:151-156, 1977.
197.

198.

Oates, J.A., R. Whorten, J.F. Gerkens, R.A. Branch, J.W. Hoi 1ifield,
and J.C. Frolich:

The participation of prostaglandins in the control

of renin release.

Fed. Proc. 38:72-74, 1979.

Ofstad, J., Y. Willassen, and K.E. Egenberg:

Distribution of radio¬

isotope labeled microparticles in the renal cortex of dogs in hemor¬
rhagic hypotension.

Scand. J. Clin. Lab.

Invest. 31:277-287, 1973.

104.

199.

Ogletree, M.L., A.C. Beardsley, and A.M. Lefer:
prostaglandins on isolated cat cardiac tissue.

Myocardial actions of
Life Sci. 16:1923-1929,

1975.
200.

Oken, D.E.:

Role of prostaglandin in acute renal failure.

Lancet 1:

1319-1322, 1975.
201.

Orloff, J., J.S. Handler, and J. Bergstrom:

Effect of prostaglandin E-j

on the permeability response of toad bladder to vasopressin, theo¬
phylline, and adenosine 3', 5'-monophosphate.

Nature, Lond. 205:397-

398, 1965.
202.

Papanicolaou, N. and P. Meyer:

Inactivation of prostaglandins E^ and

A^ on their single passage through the pulmonary vascular bed in anes¬
thetized rats.
203

Rev. Can. Biol. 31:313-316, 1972.

Parratt, J.R. and R.M. Sturgess:

The effect of indomethacin on the

cardiovascular and metabolic responses in E. coli endotoxin in the cat.
Br. J. Pharmac. 50:177-183, 1974.
204.

Parratt, J.R. and R.M. Sturgess:

The protective effect of sodium

meclofenamate in experimental endotoxin shock.

Br. J. Pharmac. 53:

466P, 1975.
205.

Parratt, J.R. and R.M. Sturgess:

Evidence that prostaglandin release

mediates pulmonary vasoconstriction induced by E. coli endotoxin.

J.

Physiol. 246:79P-80P, 1975.
206.

Parratt, J.R. and R.M. Sturgess:

The effect of a new anti-inflammatory

drug, flurbiprofen, on the respiratory, hemodynamic, and metabolic re¬
sponses to E. coli endotoxin shock in the cat.
551, 1976.

Br. J. Pharmac. 58:547-

105.

207.

Pek, S., T-Y. Tai, and A. Elster:

Stimulatory effects of prostaglandins

E-| , E^, and F^ on glucagon and insulin release in vitro .

Diabetes

27:801-809, 1978.
208.

Pong, S.S. and L. Levine:

Prostaglandin biosynthesis and metabolism

as measured by radioimmunoassay.
Ramwell, ed.. New York:
209.

The Prostaglandins, Vol. 3, P.W.

Plenum Press, pp. 41-76, 1977.

Postel, J., P.R. Schloerb, and D. Furtado:

Pathophysiologic alterations

during bacterial infusions for the study of bacteremic shock.

Surgery,

Gynec. Obstet. 141:683-692, 1975.
210.

Prancan, A.V. and J. Nakano:

Effect of glucocorticoid on the prosta¬

glandin dehydrogenase activity in the lung of endotoxemic rats.
Pharmacologist 16:197, 1974.
211.

Priano, L.L., T.H. Miller, and D.L. Traber:

Use of prostaglandin E-j

in the treatment of experimental hypovolemic shock.

Circ. Shock 1:221-

230, 1974.
212.

Raflo, G.T., S.L. Wangensteen, T.M. Glenn, and A.M. Lefer:

Mechanism

of the protective effects of prostaglandins E-, and F^ in canine endo¬
toxin shock.
213.

Eur. J. Pharmac. 24:86-95, 1973.

Ramwell, P.W. and E.G. Daniels:

Chromatography of the prostaglandins.

Lipid Chromatographic Analysis, Vol.

II, G.V. Marinetti, ed., New York:

Marcel Dekker, Inc., pp. 313-344, 1969.
214.

Reichgott, M.J. and K. Engelman:
lethality of endotoxin shock.

215.

Indomethacin:

lack of effect on

Circ. Shock 2:215-219, 1975.

Richardson, P.D.I. and P.G. Withrington:

The vasodilatory actions of

isoprenaline, histamine, prostaglandin E^, glucagon, and secretin in
the hepatic arterial vascular bed of the dog.
581-588, 1976.

Br. J. Pharmac. 57:

106.

216.

Robert, A.:

Prostaglandins and the digestive system.

glandins, Vol. 3., P.W. Ramwell, ed., New York:

The Prosta-

Plenum Press, pp.

205-266, 1977.
217.

Robertson, R.P.:

Differential in vivo pulmonary degradation of prosta¬

glandins E-|, B-j, and A-j.
218.

Am. J. Physiol. 228:68-70, 1975.

Robertson, R.P. and M. Chen:

Prostaglandin modulation of plasma in¬

sulin and glucose in normal and diabetic humans.

Clin. Res. 25:128A,

1976.
219.

Robinson, B.F., J.G. Collier, S.M.M. Karim, and K. Somers:
prostaglandins A-j, l\^, E>-|,

and F^a on forearm arterial bed and

superficial hand veins in man.
220.

Rocha e Silva, M.:
of shock.

Shock:

Effect of

Clin. Sci. 44:367-376, 1973.

Participation of the kinin system in different kinds
Biochemical, Pharmacological, and Clinical Aspects,

A. Bertelli and N. Bach, eds., Adv. Exp. Med. Biol. 9, New York:
Plenum Press, pp 135-151, 1970.
221.

Roman, R.J., M.L. Kauken, N.L. Terrangno, and P. Y-K. Wong:

Inhibition

of renal prostaglandin synthesis and metabolism by indomethacin in rats.
Proc. Soc. Exp. Biol. Med. 159:165-170, 1978.
222.

Rose, J.C. and P.A. Kot:
precursors.

Cardiovascular responses to prostaglandin

The Prostaglandins, Vol. 3, P.W. Ramwell, ed., pp. 135-

144, 1977.
223.

Rosenberg, J.C., R.C. Lillehei, J. Longerbeam, and B. Zimmerman:
Studies on hemorrhagic and endotoxin shock in relation to vasomotor
changes and endogenous circulating epinephrine, norepinephrine, and
serotonin.

Ann. Surg. 154:611-628, 1961.

>•

107.

224.

Rutenburg, A.M., P. Polgar, M. Bell, and R.H. Egdahl:

Adenosine 31,

51-monophosphate metabolism in the liver in experimental hemorrhagic
shock.
225.

Surgery 74:660-665, 1973.

Sacca, L. and G. Perez:
levels in the rat.

226.

Influence of prostaglandins on plasma glucagon

Metabolism 25:127-130, 1976.

Saeed, S.A. and A.C. Roy:

Purification of 15-hydroxy prostaglandin

dehydrogenase from bovine lung.

Biochim. Biophys. Res. Commun. 47:96-

102, 1972.
227.

Said, S.I.:

The lung in relation to vasoactive hormones.

Fed. Proc.

32:1972-1976, 1973.
228.

Said, S.I.:

The prostaglandins in relation to the lung:

function, mediators of disease, or therapeutic agents?

regulators of
Bui 1. Physiopath.

Resp. 10:411-418, 1974.
229.

Samuelsson, B.:

Biosynthesis of prostaglandins.

Fed. Proc. 31:1442-

1450, 1972.
230.

Samuelsson, B., M. Goldyne, E. Granstrom, M. Hamberg, S. Hammarstrom,
and C. Malmsten:

Prostaglandins and Thromboxanes.

Ann. Rev. Biochem.

47:997-1009, 1978.
231.

Samuelsson, B., E. Granstrom, K. Grden, M. Hamberg, and S. Hammarstrom:
Prostaglandins.

232.

Ann. Rev. Biochem.

44:669-695, 1975.

Sayeed, M.M., R.M. Senior, I.H. Chaudry, and A.E. Baue:

Active Na-K

transport and ATP levels in the lung and liver during shock.

Surg.

Forum 25:5-7, 1975.
233.

Schwartz, M.L., W.R.C. Murphy, D.M. Nicoloff, and E.W. Humphrey:
Factors altering pulmonary capillary perfusion.

1974.

Surgery 75:750-754,

I

108.

234.

Selkurt, E.E.:

Role of ADH in the loss of renal concentrating ability

in primate hemorrhagic shock.

Proc. Soc. Exp. Biol. Med. 142:1310-

1315, 1973.
235.

Shatney, C.H. and R.C. Lillehei:
endotoxin shock.

236.

Prostaglandin-adenyl cyclase

Adv. Cyclic Nucleotide Res. 1:479-491, 1972.

Shaw, J.O. and K.M. Moser:
the lungs.

238.

Acta Biol. Med. Germ. 35:1141-1149, 1976.

Shaw, J.E., S.J. Jessup, and P.W. Ramwell:
relationships.

237.

Effects of prostaglandins in canine

The current status of prostaglandins and

Chest 68:75-80, 1975.

Shehadeh, Z., W.E. Price, and E.D. Jacobson:

Effects of vasoactive

agents in intestinal blood flow and motility in the dog.

Am. J. Physiol.

216:386-392, 1969.
239.

Shires, G.T.:
shock.

240.

Pathophysiology and fluid replacement in hypovolemic

Ann. Clin. Res. 9:144-150, 1977.

Shoemaker, W.C. and J.M. Reinhard:
and trauma states.

241.

242.

Prostaglandins as intracellular messen¬

Life Sci. 16:1635-1648, 1975.

Sivakoff, M., E. Pure, W. Hsueh, and P. Needleman:
the heart.

243.

Surgery, Gynec. Obstet. 137:980-986, 1973.

Silver, M.J. and J.B. Smith:
gers.

Tissue perfusion defects in shock

Prostaglandins and

Fed. Proc. 38:78-82, 1979.

Sorrells, K., E.G. Erdos, and W.H. Massion:

Effect of prostaglandin E-j

on the pulmonary vascular response to endotoxin.

Proc. Soc. Exp. Biol.

Med. 140:310-313, 1972.
244.

Stamford, I.F. and W.G. Unger:

Improved purification and chromato¬

graphy of extracts containing prostaglandins.
1972.

J. Physiol. 225:4P-5P,

109.

245.

Starling, M.B. and R.B. Elliot:

The effects of prostaglandins,

prostaglandin inhibitors, and oxygen in the closure of the ductus
arteriosus, pulmonary arteries, and umbilical vessels in vitro.
Prostaglandins 8:187-204, 1974.
246.

Staszewski-Barczak, J. and J.R. Vane:
the local control of circulation.

The role of prostaglandins in

Clin. Exp. Pharmac. Physiol. Supp.

2:71-78, 1975.
247.

Su, J.Y., C.B. Higgins, and W.F. Friedman:
effects of prostaglandins E-j , A-j , and
tissue.

248.

Chronotropic and inotropic
on isolated mammalian cardiac

Proc. Soc. Exp. Biol. Med. 143:1227-1230, 1973.

Subbiah, M.T.R.:

Prostaglandins and the arterial wall:

research on the pathogenesis of atherosclerosis.

an avenue for

Mayo Clin. Proc. 53:

60-62, 1978.
249.

Sykes, M.K.:

Pulmonary disturbances in shock.

Experimental Aspects.

Shock:

Clinical and

I. McA. Ledingham, ed., Amsterdam:

Excerpta

Medica, pp. 21-42, 1976.
250.

Tai, H-H. and C.S. Hollander:

Kinetic evidence of a distinct regulatory

site on 15-hydroxy prostaglandin dehydrogenase.

Adv. Prostaglandin

Thromboxane Res. 1:171-175, 1976.
251.

Tateson, J.E., S. Moncada, and J.R. Vane:

Effects of prostacyclin on

cyclic AMP concentrations in human platelets.

Prostaglandins 13:389-

397, 1977.
252.

Terashita, Z., H. Fukui, K. Nishikawa, M. Hirata, and S. Kikuchi:
Coronary vasospastic action of thromboxane A^ in isolated, working
guinea-pig hearts.

Eur. J. Pharmac. 53:49-56, 1978.

.

no.
253.

Thomas, G. and G.B. West:
responses.

254.

Prostaglandins as regulators of bradykinin

J. Pharm. Pharmac. 25:747-748, 1973.

Tiefenbrun, J., S. Dikman, and W.C. Shoemaker:

The correlation of se¬

quential changes in the distribution of pulmonary blood flow in hemor¬
rhagic shock with the histopathologic anatomy.

Surgery 78:618-627,

1975.
255.

Tiefenbrun, J., S.I. Kim, and W.C. Shoemaker:

The relation of the dis

tribution of pulmonary blood flow to lung function during hemorrhagic
shock.
256.

Surgery, Gynec. Obstet. 138:557-561, 1974.

Tobian, L. and M. O'Donnell:

Renal prostaglandins in relation to

sodium regulation and hypertension.
257.

258.

Fed. Proc. 35:2388-2392, 1976.

Tomasi, V. :

Prostaglandin E as an intracellular regulator of cyclic

AMP levels.

Exp. Cell Biol. 44:260-277, 1976.

Torres, V.E., J.C. Romero, C.G. Strong, D.M. Wilson, and V.R. Walker:
Renal prostaglandin E during acute renal failure.

Prostaqlandins8:353

360, 1974.
259.

Tyssebotn, I. and A. Kirkeb0:

The effect of indomethacin on renal

blood flow distribution during hemorrhagic shock in dogs.

Acta

Physiol. Scand. 101:15-21, 1977.
260.

Ulevitch, R.J., C.G. Cochrane, P.M. Henson, D.C. Morrison, and W.F.
Roe:

Mediation systems in bacterial 1ipopolysaccharide-induced hypo¬

tension and disseminated intravascular coasgulation.
complement.
261.

I.

The role of

J. Exp. Med. 142:1570-1590, 1975.

Urbani, A.I. and P.D. Maragno:
apparato cardiovascolare.

Prostaglandine.

I

Prostaglandine ed

G. Ital. Cardiol. 8:451-462, 1978.

111.

262.

Vane, J.R.:
lation.

263.

The release and fate of vasoactive hormones in the circu¬

Br. J. Pharmac. 35:209-242, 1969.

Vane, J.R. and J.C. McGiff:

Possible contributions of endogenous

prostaglandins to control of blood pressure.

Circ. Res. 36-37 (Supp.

I)

1-68 - 1-75, 1975
264.

Weeks, J.R.:

Prostaglandins.

Ann. Rev. Pharmac. 12:317-336, 1972.

265.

Weeks, J.R.:

Introduction to cardiovascular research on prostaglandins.

Adv. Prostaglandin Thromboxane Res. 1:395-401, 1976.
266.

Weil, M.:

Current understanding of mechanisms and treatment of circu¬

latory shock caused by bacterial infections.

Ann. Clin. Res. 9:181-191,

1977.
267.

Weil, M.H., H. Shubin, and M. Biddle:
organisms.

268.

Ann.

269.

Int. Med. 60:384-400, 1964.

Weiner, R. and G. Kaley:
vascular bed.

Influence of prostaglandin E-| in the terminal

Am. J. Physiol. 217:563-566, 1969.

Weir, E.K. and R.F. Grover:
the pulmonary circulation.

270.

Shock caused by gram-negative

The role of endogenous prostaglandins in
Anesthesiology 48:201-212, 1978.

Werb, R., R.R. Bailey, R.M. Lindsay, W.F. Clark, and A.L. Linton:
Different effects of prostaglandin E^ in two models of experimental
acute renal failure.

271.

Kidney Inter. 14:734, 1978.

Wichterman, K.A., A.E. Baue, and I.H. Chaudry:
a review of laboratory models and a proposal.

272.

Wichterman, K.A., I.H. Chaudry, and A.E. Baue:
glucose uptake during sepsis.

273.

Sepsis and septic shock:
Submitted for publication.
Studies of peripheral

Arch Surg., in press.

Wicks, T.C., J.C. Rose, M. Johnson, P.W. Ramwell, and P.A. Kot:
of arachadonic acid on the canine pulmonary circulation.
34:438, 1975.

Effect

Fed. Proc.

112.

274.

Wilkens, H., N. Bach, R. Steger, and J. Korn:
pH on peripheral vascular tone:
peptides.

Shock:

The influence of blood

possible roles of proteases and vaso-

Biochemical, Pharmacological, and Clinical Aspects,

A. Bertelli and N. Bach, eds.. New York:

Plenum Press, pp. 201-224,

1970.
275.

Winslow, E.J., H.S. Loeb, S.H. Rahimtoola, S. Kamath, and R.M. Gunnar:
Hemodynamic studies and results of therapy in 50 patients with bacterremicshock.

276.

Am. J. Med. 54:421-423, 1973.

Young, L.S., W.J. Martin, R.D. Meyer, R.J. Weinstein, and E.T. Anderson
Gram-negative rod bacteremia:
peutic considerations.

277.

Ann.

microbiologic, immunologic, and thera¬
Int. Med. 86:456-471, 1977.

Yun, J.,G. Kelly, F.C. Bartter, and H. Smith, Jr.:

Role of prosta¬

glandins in the control of renin secretion in the dog.

Circ. Res. 40:

459-464, 1977.
278.

Zenser, T.V., A.C. Herman, and B.B. Davis:

Mechanism of Ca

increases in renal prostaglandin synthesis.
279.

2+

-mediated

Kidney Inter. 14:786, 1978

Zijlstra, W.G., J.R. Brunsting, F. Ten Hoor, and A.J. Hergroesen:
Prostaglandin E-j and cardiac arrhythmia.

Eur. J. Pharmac. 18:392-395,

1972.
280.

Zins, G.R.:

Renal prostaglandins.

281.

Zweifach, B.W. and A. Fronek:

Am. J. Med. 58:14-24, 1975.

The interplay of central and peripheral

factors in irreversible hemorrhagic shock.
147-180, 1975.

Prog. Cardiovasc. Pis. 18:

YALE MEDICAL LIBRARY
Manuscript Theses

Unpublished theses submitted for the Master's and Doctor's degrees and
deposited in the Yale Medical Library are to be used only with due regard to the
rights of the authors.
Bibliographical references may be noted, but passages
must not be copied without permission of the authors, and without proper credit
being given in subsequent written or published work.

This thesis by
has been
used by the following persons, whose signatures attest their acceptance of the
above restrictions.

NAME AND ADDRESS

DATE

